Publications
Selected publications
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial (Journal article - 2018)
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications (Journal article - 2021)
- The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial (Journal article - 2021)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (Journal article - 2021)
- Economic impacts of overweight and obesity: current and future estimates for eight countries (Journal article - 2021)
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. (Journal article - 2019)
- Should obesity be recognised as a disease? (Journal article - 2019)
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (Journal article - 2022)
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. (Journal article - 2024)
- Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation (Journal article - 2022)
2024
Efficacy of providing energy expenditure information to guide weight loss interventions in people with obesity: A randomized controlled trial.
Lim, J. Z. M., Williams, A., Burgess, J., O'Connell, J., James, M., Cross, A., . . . Wilding, J. P. H. (2024). Efficacy of providing energy expenditure information to guide weight loss interventions in people with obesity: A randomized controlled trial.. Clinical obesity, e12703. doi:10.1111/cob.12703
Evaluating the impact of differing completion rates of a face-to-face DIABETES self-management education programme on Patient Reported Outcome measures (DIABETES PRO): A feasibility trial protocol.
Lewis, G., Irving, G., Wilding, J., & Hardy, K. (2024). Evaluating the impact of differing completion rates of a face-to-face DIABETES self-management education programme on Patient Reported Outcome measures (DIABETES PRO): A feasibility trial protocol.. Diabetic medicine : a journal of the British Diabetic Association, e15430. doi:10.1111/dme.15430
Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation.
Valabhji, J., Gorton, T., Barron, E., Safazadeh, S., Earnshaw, F., Helm, C., . . . Bakhai, C. (2024). Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation.. The lancet. Diabetes & endocrinology, S2213-8587(24)00194-3. doi:10.1016/s2213-8587(24)00194-3
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.
Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., . . . Alam, U. (2024). Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.. EClinicalMedicine, 75, 102777. doi:10.1016/j.eclinm.2024.102777
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., . . . Lincoff, A. M. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.. Nature medicine, 30(7), 2058-2066. doi:10.1038/s41591-024-03015-5
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., . . . Kushner, R. F. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.. Nature medicine, 30(7), 2049-2057. doi:10.1038/s41591-024-02996-7
1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58
MI KANG, Y. U., MELLONI, G. E. M., CAHN, A., RAZ, I., MOURA, F., BHATT, D. L., . . . WIVIOTT, S. D. (2024). 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58. Diabetes, 73(Supplement_1). doi:10.2337/db24-1896-lb
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., . . . Wright, E. E. (2024). DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. Metabolism: clinical and experimental, 155931. doi:10.1016/j.metabol.2024.155931
The double burden of malnutrition in individuals: Identifying key challenges and re-thinking research focus.
Kiosia, A., Dagbasi, A., Berkley, J. A., Wilding, J. P. H., Prendergast, A. J., Li, J. V., . . . Frost, G. (2024). The double burden of malnutrition in individuals: Identifying key challenges and re-thinking research focus.. Nutrition bulletin, 49(2), 132-145. doi:10.1111/nbu.12670
Obesity pharmacotherapy in older adults: a narrative review of evidence.
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2024). Obesity pharmacotherapy in older adults: a narrative review of evidence.. International journal of obesity (2005). doi:10.1038/s41366-024-01529-z
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Eleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., . . . Alam, U. (2024). Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.. Diabetologia. doi:10.1007/s00125-024-06132-5
SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
Seidu, S., Alabraba, V., Davies, S., Newland-Jones, P., Fernando, K., Bain, S. C., . . . Wilding, J. P. H. (2024). SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.. Diabetes therapy : research, treatment and education of diabetes and related disorders. doi:10.1007/s13300-024-01550-5
Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.
Papamargaritis, D., Al-Najim, W., Lim, J. Z. M., Crane, J., Bodicoat, D. H., Barber, S., . . . Davies, M. J. (2024). Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.. The Lancet regional health. Europe, 39, 100853. doi:10.1016/j.lanepe.2024.100853
SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL
Haller, P., Wiviott, S., Jarolim, P., Goodrich, E. L., Bhatt, D. L., Gause-Nilsson, I., . . . Morrow, D. A. (2024). SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL. Journal of the American College of Cardiology, 83(13), 378. doi:10.1016/s0735-1097(24)02368-4
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.
Miller, J. L., Gevers, E., Bridges, N., Yanovski, J. A., Salehi, P., Obrynba, K. S., . . . C601/C602 Investigators. (2024). Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.. Obesity (Silver Spring, Md.), 32(2), 252-261. doi:10.1002/oby.23928
Changing the global obesity narrative to recognize and reduce weight stigma: A position statement from the World Obesity Federation.
Nutter, S., Eggerichs, L. A., Nagpal, T. S., Ramos Salas, X., Chin Chea, C., Saiful, S., . . . Yusop, S. (2024). Changing the global obesity narrative to recognize and reduce weight stigma: A position statement from the World Obesity Federation.. Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(1), e13642. doi:10.1111/obr.13642
2023
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.
Zhu, J., & Wilding, J. P. H. (2023). Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.. Current atherosclerosis reports. doi:10.1007/s11883-023-01181-4
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.
Patel, S. M., Morrow, D. A., Bellavia, A., Berg, D. D., Bhatt, D. L., Jarolim, P., . . . Bohula, E. A. (2023). Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.. European journal of heart failure. doi:10.1002/ejhf.3118
Drugs That Affect Body Weight
Asswad, R. G., & Wilding, J. P. H. (2023). Drugs That Affect Body Weight. In Handbook of Obesity - Volume 2 (pp. 367-375). CRC Press. doi:10.1201/9781003432807-39
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)
Rajeev, S., Roberts, C., Brown, E., Sprung, V., Harrold, J., Halford, J., . . . Wilding, J. (2023). No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE). Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics. doi:10.1111/dom.15257
Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers
Lim, J. Z. M., Burgess, J., Ooi, C., Ferdousi, M., Azmi, S., Kalteniece, A., . . . Alam, U. (2023). Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers. DIAGNOSTICS, 13(17). doi:10.3390/diagnostics13172793
Obesity: medical management
Henney, A. E., & Wilding, J. P. H. (2023). Obesity: medical management. Medicine, 51(7), 509-514. doi:10.1016/j.mpmed.2023.04.009
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial
Miller, J. L., Gevers, E., Bridges, N., Yanovski, J. A., Salehi, P., Obrynba, K. S., . . . Bhatnagar, A. (2023). Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 108(7), 1676-1685. doi:10.1210/clinem/dgad014
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial
Zelniker, T. A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Jarolim, P., Cahn, A., . . . Morrow, D. A. (2023). Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial. JAMA CARDIOLOGY, 8(5), 503-509. doi:10.1001/jamacardio.2023.0019
New insights into the treatment of obesity.
Blüher, M., Aras, M., Aronne, L. J., Batterham, R. L., Giorgino, F., Ji, L., . . . Wilding, J. P. H. (2023). New insights into the treatment of obesity.. Diabetes, obesity & metabolism. doi:10.1111/dom.15077
Tirzepatide Induces Weight Loss in participants with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies
Kwan, A. Y. M., Maldonado, J. M., Wang, H., Rasouli, N., Wilding, J. P. H., & Aberle, J. (2023). Tirzepatide Induces Weight Loss in participants with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies. In Diabetologie und Stoffwechsel. Georg Thieme Verlag. doi:10.1055/s-0043-1767995
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Schechter, M., Wiviott, S., Raz, I., Goodrich, E. L., Rozenberg, A., Yanuv, I., . . . Mosenzon, O. (2023). Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. LANCET DIABETES & ENDOCRINOLOGY, 11(4), 233-241. doi:10.1016/S2213-8587(23)00009-8
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R., Birkenfeld, A. L., Ceriello, A., Cheng, A., . . . Standl, E. (2023). CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. CARDIOVASCULAR DIABETOLOGY, 22(1). doi:10.1186/s12933-023-01788-6
RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
Small, A. M., Berg, D., Raz, I., Goodrich, E. L., Moura, F., Mosenzon, O., . . . Wiviott, S. D. (2023). RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58. Journal of the American College of Cardiology, 81(8), 1816. doi:10.1016/s0735-1097(23)02260-x
Adipocytes in obesity: A perfect reservoir for SARS-CoV-2?
Zhu, J., Wilding, J. P. H., & Hu, J. (2023). Adipocytes in obesity: A perfect reservoir for SARS-CoV-2?. MEDICAL HYPOTHESES, 171. doi:10.1016/j.mehy.2023.111020
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
Pollack, R., Raz, I., Wiviott, S. D., Goodrich, E. L., Murphy, S. A., Yanuv, I., . . . Cahn, A. (2023). Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. DIABETES CARE, 46(1), 156-164. doi:10.2337/dc22-1318
Etiopathogenesis of Obesity
Rajeev, S. P., & Wilding, J. P. H. (2023). Etiopathogenesis of Obesity. In Obesity, Bariatric and Metabolic Surgery (pp. 15-26). Springer International Publishing. doi:10.1007/978-3-030-60596-4_2
2022
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
Lopez-Jimenez, F., Almahmeed, W., Bays, H., Cuevas, A., Di Angelantonio, E., le Roux, C. W., . . . Wilding, J. P. H. (2022). Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 29(17), 2218-2237. doi:10.1093/eurjpc/zwac187
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., . . . le Roux, C. W. (2022). Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. DIABETES CARE, 45(10), 2396-2405. doi:10.2337/dc21-1785
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Mosenzon, O., Raz, I., Wiviott, S. D., Schechter, M., Goodrich, E. L., Yanuv, I., . . . Sabatine, M. S. (2022). Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. DIABETES CARE, 45(10), 2350-2359. doi:10.2337/dc22-0382
Economic impacts of overweight and obesity: current and future estimates for 161 countries
Okunogbe, A., Nugent, R., Spencer, G., Ralston, J., & Wilding, J. (2022). Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ GLOBAL HEALTH, 7(9). doi:10.1136/bmjgh-2022-009773
A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol
Swancutt, D., Tarrant, M., Ingram, W., Baldrey, S., Burns, L., Byng, R., . . . Pinkney, J. (2022). A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol. PILOT AND FEASIBILITY STUDIES, 8(1). doi:10.1186/s40814-022-01167-0
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial
Oyama, K., Raz, I., Cahn, A., Goodrich, E. L., Bhatt, D. L., Leiter, L. A., . . . Wiviott, S. D. (2022). Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA CARDIOLOGY, 7(9), 914-923. doi:10.1001/jamacardio.2022.2006
Exercise in Obesity-the Role of Technology in Health Services: Can This Approach Work?
Dobbie, L. J., Tahrani, A., Alam, U., James, J., Wilding, J., & Cuthbertson, D. J. (2022). Exercise in Obesity-the Role of Technology in Health Services: Can This Approach Work?. CURRENT OBESITY REPORTS, 11(3), 93-106. doi:10.1007/s13679-021-00461-x
The Peripheral Neuropathy Prevalence and Characteristics Are Comparable in People with Obesity and Long-Duration Type 1 Diabetes
Lim, J. Z. M., Burgess, J., Ooi, C. G., Ponirakis, G., Malik, R. A., Wilding, J. P. H., & Alam, U. (n.d.). The Peripheral Neuropathy Prevalence and Characteristics Are Comparable in People with Obesity and Long-Duration Type 1 Diabetes. Advances in Therapy. doi:10.1007/s12325-022-02208-z
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
Oyama, K., Raz, I., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., . . . Wiviott, S. D. (2022). Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. EUROPEAN HEART JOURNAL, 43(31), 2958-2967. doi:10.1093/eurheartj/ehab530
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., . . . Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. DIABETES OBESITY & METABOLISM, 24(8), 1553-1564. doi:10.1111/dom.14725
MRI thigh measurements predict whole‐body skeletal muscle mass in patients with type 2 diabetes: a comparison with DXA
Brown, E., Williams, A., Hakim, O., Wilton, M. M., Harrold, J. A., Hughes, D., . . . Cuthbertson, D. J. (2022). MRI thigh measurements predict whole‐body skeletal muscle mass in patients with type 2 diabetes: a comparison with DXA. JCSM Rapid Communications, 5(2), 149-153. doi:10.1002/rco2.70
A systematic review of interventions to increase physical activity and reduce sedentary behaviour following bariatric surgery
James, J. D., Hardeman, W., Goodall, M., Eborall, H., Sprung, V. S., Bonnett, L. J., & Wilding, J. P. H. (2022). A systematic review of interventions to increase physical activity and reduce sedentary behaviour following bariatric surgery. PHYSIOTHERAPY, 115, 1-17. doi:10.1016/j.physio.2021.10.002
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., . . . Wiviott, S. D. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. CIRCULATION, 145(21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103
The UK's U-turn on obesity is a failure of leadership
Buse, K., Wilding, J., Bryant, M., Halford, J. C. G., & Ralston, J. (2022). The UK's U-turn on obesity is a failure of leadership. BMJ-BRITISH MEDICAL JOURNAL, 377. doi:10.1136/bmj.o1285
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial
Sargeant, J. A., King, J. A., Yates, T., Redman, E. L., Bodicoat, D. H., Chatterjee, S., . . . Davies, M. J. (2022). The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial. DIABETES OBESITY & METABOLISM. doi:10.1111/dom.14721
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
Wilding, J. P. H., Evans, M., Fernando, K., Luis Gorriz, J., Cebrian, A., Diggle, J., . . . Del Prato, S. (2022). The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. DIABETES THERAPY, 13(5), 847-872. doi:10.1007/s13300-022-01228-w
Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Cahn, A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Murphy, S. A., Yanuv, I., . . . Raz, I. (2022). Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. DIABETES CARE, 45(4), 938-946. doi:10.2337/dc21-1744
Adjunctive Therapy, Including Pharmacotherapy
Al‐Bazz, D., & Wilding, J. P. H. (2022). Adjunctive Therapy, Including Pharmacotherapy. In Unknown Book (pp. 279-296). Wiley. doi:10.1002/9781119695257.ch21
Clinical Obesity in Adults and Children
Kopelman, P. G., Caterson, I. D., Dietz, W. H., Armstrong, S., Sweeting, A. N., & Wilding, J. P. H. (Eds.) (2022). Clinical Obesity in Adults and Children. Wiley. doi:10.1002/9781119695257
FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
Berg, D., Wiviott, S. D., Raz, I., Jarolim, P., Goodrich, E. L., Mosenzon, O., . . . Morrow, D. A. (2022). FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 79 (pp. 1526). Retrieved from https://www.webofscience.com/
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
Kolkailah, A. A., Wiviott, S. D., Raz, I., Murphy, S. A., Mosenzon, O., Bhatt, D. L., . . . McGuire, D. K. (2022). Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. DIABETES CARE, 45(2), E27-E29. doi:10.2337/dc21-1668
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy
Frias, J. P., Maaske, J., Suchower, L., Johansson, L., Hockings, P. D., Iqbal, N., & Wilding, J. P. H. (2022). Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. DIABETES OBESITY & METABOLISM, 24(1), 61-71. doi:10.1111/dom.14548
Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through SURPASS-5 studies
Wilding, J. P. H., Kwan, A. Y. M., Maldonado, J. M., Wang, H., & Rasouli, N. (2022). Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through SURPASS-5 studies. In DIABETOLOGIA Vol. 65 (pp. S289). Retrieved from https://www.webofscience.com/
2021
PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviouR after barIatric Surgery
James, J., Hardeman, W., Eborall, H., Goodall, M., & Wilding, J. (2021). PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviouR after barIatric Surgery. BMJ OPEN, 11(12). doi:10.1136/bmjopen-2021-051638
Economic impacts of overweight and obesity: current and future estimates for eight countries
Okunogbe, A., Nugent, R., Spencer, G., Ralston, J., & Wilding, J. (2021). Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ GLOBAL HEALTH, 6(10). doi:10.1136/bmjgh-2021-006351
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
Berg, D. D., Wiviott, S. D., Scirica, B. M., Zelniker, T. A., Goodrich, E. L., Jarolim, P., . . . Morrow, D. A. (2021). A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. DIABETES CARE, 44(11), 2573-2581. doi:10.2337/dc21-1170
Metabolically healthy obesity: time for a change of heart?
Cuthbertson, D. J., & Wilding, J. P. H. (2021). Metabolically healthy obesity: time for a change of heart?. NATURE REVIEWS ENDOCRINOLOGY, 17(9), 519-520. doi:10.2337/dc20-2227(2021)
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., . . . Raz, I. (2021). The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. DIABETES CARE, 44(8), 1805-1815. doi:10.2337/dc21-0076
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
Khunti, K., Kosiborod, M., Kim, D. J., Kohsaka, S., Lam, C. S. P., Goh, S. -Y., . . . Fenici, P. (2021). Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. CARDIOVASCULAR DIABETOLOGY, 20(1). doi:10.1186/s12933-021-01345-z
Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Nicholson, M. K., Ghazal Asswad, R., & Wilding, J. P. (2021). Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.. Expert opinion on pharmacotherapy, 1-8. doi:10.1080/14656566.2021.1953471
A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
Brown, E., Wilton, M. M., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stancak, A., . . . Cuthbertson, D. J. (2021). A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. BMJ open, 11(7), e045663. doi:10.1136/bmjopen-2020-045663
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021). SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. LANCET, 398(10296), 262-276. doi:10.1016/S0140-6736(21)00536-5
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Javor, E., Lucijanic, M., & Skelin, M. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEW ENGLAND JOURNAL OF MEDICINE, 385(1). doi:10.1056/NEJMc2106918
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Srivastava, G., & Kumar, R. B. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Javor, E., Lucijanić, M., & Skelin, M. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Nadolsky, K. Z., & Agarwal, M. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Khoo, T. K., & Lin, J. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918
Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.
Rosen, C. J., & Ingelfinger, J. R. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.. The New England journal of medicine, 385(1), e4. doi:10.1056/nejmc2106918
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
Evans, M., Morgan, A. R., Yousef, Z., Ellis, G., Dashora, U., Patel, D. C., . . . Bain, S. C. (2021). Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. DRUGS, 81(11), 1243-1255. doi:10.1007/s40265-021-01538-6
Realising the full potential of data-enabled trials in the UK: a call for action
Sydes, M. R., Barbachano, Y., Bowman, L., Denwood, T., Farmer, A., Garfield-Birkbeck, S., . . . Grp, D. E. T. (2021). Realising the full potential of data-enabled trials in the UK: a call for action. BMJ OPEN, 11(6). doi:10.1136/bmjopen-2020-043906
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58
Zelniker, T. A., Morrow, D. A., Mosenzon, O., Goodrich, E. L., Jarolim, P., Murphy, S. A., . . . Wiviott, S. D. (2021). Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. EUROPEAN JOURNAL OF HEART FAILURE, 23(6), 1026-1036. doi:10.1002/ejhf.2073
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
O'Donoghue, M. L., Kato, E. T., Mosenzon, O., Murphy, S. A., Cahn, A., Herrera, M., . . . Wiviott, S. D. (2021). The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. DIABETOLOGIA, 64(6), 1226-1234. doi:10.1007/s00125-021-05399-2
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
Cahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Goodrich, E. L., . . . Wiviott, S. D. (2021). Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. DIABETES CARE, 44(5), 1159-1167. doi:10.2337/dc20-2492
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
Wharton, S., Astrup, A., Endahl, L., Lean, M. E. J., Satylganova, A., Skovgaard, D., . . . Wilding, J. P. H. (2021). Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. INTERNATIONAL JOURNAL OF OBESITY, 45(5), 923-933. doi:10.1038/s41366-020-00733-x
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., . . . Wiviott, S. D. (2021). Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.. JAMA Cardiology. doi:10.1001/jamacardio.2021.0660
Short-Term Physical Inactivity Induces Endothelial Dysfunction
Davies, K. A. B., Norman, J. A., Thompson, A., Mitchell, K. L., Harrold, J. A., Halford, J. C. G., . . . Sprung, V. S. (2021). Short-Term Physical Inactivity Induces Endothelial Dysfunction. FRONTIERS IN PHYSIOLOGY, 12. doi:10.3389/fphys.2021.659834
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial
McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause-Nilsson, I. A. M., Bhatt, D. L., . . . Wilding, J. P. H. (2021). The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM, 23(4), 1020-1029. doi:10.1111/dom.14308
Design of a randomised controlled trial: does indirect calorimetry energy information influence weight loss in obesity?
Lim, J., Alam, U., Cuthbertson, D., & Wilding, J. (2021). Design of a randomised controlled trial: does indirect calorimetry energy information influence weight loss in obesity?. BMJ Open, 11(3), e044519. doi:10.1136/bmjopen-2020-044519
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., . . . Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEW ENGLAND JOURNAL OF MEDICINE, 384(11), 989-1002. doi:10.1056/NEJMoa2032183
The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review
Eleftheriadou, A., Williams, S., Nevitt, S., Brown, E., Roylance, R., Wilding, J. P. H., . . . Alam, U. (2021). The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. DIABETOLOGIA, 64(2), 288-303. doi:10.1007/s00125-020-05316-z
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58
Cahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., . . . Raz, I. (2021). Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58. DIABETES OBESITY & METABOLISM, 23(1), 29-38. doi:10.1111/dom.14179
Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., . . . Le Roux, C. W. (2021). Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial. In DIABETOLOGIA Vol. 64 (pp. 234). Retrieved from https://www.webofscience.com/
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Brown, E., Wilding, J. P. H., Alam, U., Barber, T. M., Karalliedde, J., & Cuthbertson, D. J. (2021). The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. ANNALS OF MEDICINE, 53(1), 2072-2089. doi:10.1080/07853890.2020.1841281
2020
Strengthening resistance to the COVID-19 pandemic and fostering future resilience requires concerted action on obesity.
Jackson-Morris, A. M., Nugent, R., Ralston, J., Barata Cavalcante, O., & Wilding, J. (2020). Strengthening resistance to the COVID-19 pandemic and fostering future resilience requires concerted action on obesity.. Global Health Action, 13(1), 1804700. doi:10.1080/16549716.2020.1804700
Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence
McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., . . . Kosiborod, M. (2020). Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. DIABETES OBESITY & METABOLISM, 22(12), 2364-2374. doi:10.1111/dom.14162
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
Wheeler, D. C., James, J., Patel, D., Viljoen, A., Ali, A., Evans, M., . . . Wilding, J. (2020). SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. DIABETES THERAPY, 11(12), 2757-2774. doi:10.1007/s13300-020-00930-x
Weight loss is the major player in bariatric surgery benefits
Wilding, J. (2020). Weight loss is the major player in bariatric surgery benefits. NATURE MEDICINE, 26(11), 1678-1679. doi:10.1038/s41591-020-1117-8
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., . . . Wilding, J. (2020). Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ OPEN DIABETES RESEARCH & CARE, 8(2). doi:10.1136/bmjdrc-2020-001706
Cardiovascular outcome trials in obesity: A review.
Wilding, J. P. H., & Jacob, S. (2020). Cardiovascular outcome trials in obesity: A review.. Obesity reviews : an official journal of the International Association for the Study of Obesity. doi:10.1111/obr.13112
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
Bonaca, M. P., Wiviott, S. D., Zelniker, T. A., Mosenzon, O., Bhatt, D. L., Leiter, L. A., . . . Sabatine, M. S. (2020). Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142(8), 734-747. doi:10.1161/CIRCULATIONAHA.119.044775
Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status
Sprung, V. S., Davies, K. A. B., Norman, J. A., Thompson, A., Mitchell, K. L., Wilding, J. P. H., . . . Cuthbertson, D. J. (2020). Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 183(2), 211-220. doi:10.1530/EJE-20-0098
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study
Cahn, A., Raz, I., Bonaca, M., Mosenzon, O., Murphy, S. A., Yanuv, I., . . . Leiter, L. A. (2020). Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. DIABETES OBESITY & METABOLISM, 22(8), 1357-1368. doi:10.1111/dom.14041
Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)
Sprung, V. S., Kemp, G. J., Wilding, J. P., Adams, V., Murphy, K., Burgess, M., . . . Cuthbertson, D. J. (2020). Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). BMJ OPEN, 10(7). doi:10.1136/bmjopen-2020-038856
Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes
Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides-Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020). Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes. Diabetic Medicine. doi:10.1111/dme.14356
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial
Bajaj, H. S., Raz, I., Mosenzon, O., Murphy, S. A., Rozenberg, A., Yanuv, I., . . . Cahn, A. (2020). Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM, 22(7), 1122-1131. doi:10.1111/dom.14011
Cover Image, Volume 22, Issue 7
Johansson, L., Hockings, P. D., Johnsson, E., Dronamraju, N., Maaske, J., Garcia‐Sanchez, R., & Wilding, J. P. H. (2020). Cover Image, Volume 22, Issue 7. Diabetes, Obesity and Metabolism, 22(7). doi:10.1111/dom.14113
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
Johansson, L., Hockings, P. D., Johnsson, E., Dronamraju, N., Maaske, J., Garcia-Sanchez, R., & Wilding, J. P. H. (2020). Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. DIABETES OBESITY & METABOLISM, 22(7), 1094-1101. doi:10.1111/dom.14004
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Kohsaka, S., Lam, C. S. P., Kim, D. J., Cavender, M. A., Norhammar, A., Jorgensen, M. E., . . . Kosiborod, M. (2020). Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. LANCET DIABETES & ENDOCRINOLOGY, 8(7), 606-615. Retrieved from https://www.webofscience.com/
Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58
Cahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S., Goodrich, E. L., Yanuv, I., . . . Raz, I. (2020). Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58. In DIABETES Vol. 69. doi:10.2337/db20-1101-P
Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial
Raz, I., Wiviott, S. D., Heerspink, H. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., . . . Mosenzon, O. (2020). Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial. In DIABETES Vol. 69. doi:10.2337/db20-303-OR
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., . . . Rubino, D. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. OBESITY, 28(6), 1050-1061. doi:10.1002/oby.22794
The 1α,25(OH)2D3 Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK Signaling.
Zhu, J., & Wilding, J. P. H. (2020). The 1α,25(OH)2D3 Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK Signaling.. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 1715-1724. doi:10.2147/dmso.s245080
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
Zelniker, T. A., Bonaca, M. P., Furtado, R. H. M., Mosenzon, O., Kuder, J. F., Murphy, S. A., . . . Wiviott, S. D. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial. CIRCULATION, 141(15), 1227-1234. doi:10.1161/CIRCULATIONAHA.119.044183
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
Freemantle, N., Mauricio, D., Giaccari, A., Bailey, T., Roussel, R., Franco, D., . . . Investigator, R. E. G. A. I. N. (2020). Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 36(4), 571-581. doi:10.1080/03007995.2019.1708287
EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
Oyama, K., Raz, I., Cahn, A., Kuder, J., Murphy, S., Bhatt, D., . . . Wiviott, S. D. (2020). EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 75 (pp. 660). Retrieved from https://www.webofscience.com/
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
Papamargaritis, D., Al-Najim, W., Lim, J., Crane, J., Lean, M., Le Roux, C., . . . Davies, M. J. (2020). Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ OPEN, 10(2). doi:10.1136/bmjopen-2019-034137
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Cahn, A., Mosenzon, O., Wiviott, S. D., Rozenberg, A., Yanuv, I., Goodrich, E. L., . . . Raz, I. (2020). Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. DIABETES CARE, 43(2), 468-475. doi:10.2337/dc19-1476
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Al-Bazz, D. Y., & Wilding, J. P. (2020). Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.. Future Cardiol. doi:10.2217/fca-2019-0065
Accessible indices of insulin resistance: exploring the associations with hepatic and intramuscular fat accumulation
Davies, K. B., Sprung, V. S., Norman, J. A., Thompson, A., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2020). Accessible indices of insulin resistance: exploring the associations with hepatic and intramuscular fat accumulation. In DIABETOLOGIA Vol. 63 (pp. S224-S225). Retrieved from https://www.webofscience.com/
Cardiorenal and metabolic outcomes of dapagliflozin vs placebo in patients at high cardiovascular risk without established cardiovascular disease: analyses from the DECLARE-TIMI 58 study
Cahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Bhatt, D. L., . . . Wiviott, S. D. (2020). Cardiorenal and metabolic outcomes of dapagliflozin vs placebo in patients at high cardiovascular risk without established cardiovascular disease: analyses from the DECLARE-TIMI 58 study. In DIABETOLOGIA Vol. 63 (pp. S269). Retrieved from https://www.webofscience.com/
DAPAGLIFLOZIN PLUS SAXAGLIPTIN ADD-ON TO METFORMIN MAINTAINS REDUCED LIVER FAT AND ADIPOSE TISSUE VOLUMES IN PATIENTS WITH TYPE 2 DIABETES OVER 122 WEEKS
Johansson, L., Hockings, P., Frias, J. P., Suchower, L., Maaske, J., Iqbal, N., & Wilding, J. P. H. (2020). DAPAGLIFLOZIN PLUS SAXAGLIPTIN ADD-ON TO METFORMIN MAINTAINS REDUCED LIVER FAT AND ADIPOSE TISSUE VOLUMES IN PATIENTS WITH TYPE 2 DIABETES OVER 122 WEEKS. In HEPATOLOGY Vol. 72 (pp. 1048). Retrieved from https://www.webofscience.com/
Effects of empagliflozin, diet, or both on physical activity and sedentary behaviour in people with type 2 diabetes: analyses from the SEESAW trial
Sargeant, J. A., King, J. A., Baldry, E. L., Bodicoat, D. H., Edwardson, C. L., Khunti, K., . . . Davies, M. J. (2020). Effects of empagliflozin, diet, or both on physical activity and sedentary behaviour in people with type 2 diabetes: analyses from the SEESAW trial. In DIABETOLOGIA Vol. 63 (pp. S270-S271). Retrieved from https://www.webofscience.com/
Endocrine testing in obesity
Wilding, J. P. H. (2020). Endocrine testing in obesity. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 182(4), C13-C15. doi:10.1530/EJE-20-0099
Is the latest evidence for cardiovascular protection with glucose-lowering medicines being implemented in clinical practice?
Al-Bazz, D. Y., & Wilding, J. P. H. (2020). Is the latest evidence for cardiovascular protection with glucose-lowering medicines being implemented in clinical practice?. In DIABETIC MEDICINE Vol. 37 (pp. 65). Retrieved from https://www.webofscience.com/
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Heerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., . . . Kosiborod, M. (2020). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. LANCET DIABETES & ENDOCRINOLOGY, 8(1), 27-35. Retrieved from https://www.webofscience.com/
Multiparametric magnetic resonance imaging of the liver demonstrates the prevalence of steatohepatitis in patients with type 2 diabetes
Brown, E., Waddell, T., Mouchti, S., Roca-Fernandez, A., Thomaides-Brears, H., Wilton, M., . . . Banerjee, R. (2020). Multiparametric magnetic resonance imaging of the liver demonstrates the prevalence of steatohepatitis in patients with type 2 diabetes. In DIABETOLOGIA Vol. 63 (pp. S420-S421). Retrieved from https://www.webofscience.com/
The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes
Davies, M. J., Baldry, E. L., Bodicoat, D. H., Chatterjee, S., Edwardson, C. L., Gray, L. J., . . . King, J. A. (2020). The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes. In DIABETOLOGIA Vol. 63 (pp. S116). Retrieved from https://www.webofscience.com/
2019
Selecting Core Outcomes for Randomised Effectiveness Trials in Type 2 Diabetes (SCORE-IT) - a Patient and Healthcare Professional Consensus on a Core Outcome Set for Type 2 Diabetes
Harman, N., Wilding, J., Curry, D., Harris, J., Logue, J., Pemberton, R. J., . . . Team, S. C. O. R. E. -I. T. S. (2019). Selecting Core Outcomes for Randomised Effectiveness Trials in Type 2 Diabetes (SCORE-IT) - a Patient and Healthcare Professional Consensus on a Core Outcome Set for Type 2 Diabetes. BMJ Open Diabetes Research and Care.
Cardiac Autonomic Neuropathy in Obesity, Metabolic Syndrome and Prediabetes: A Narrative Review (vol 10, pg 1995, 2019)
Williams, S. M., Eleftheriadou, A., Alam, U., Cuthbertson, D. J., & Wilding, J. P. H. (2019). Cardiac Autonomic Neuropathy in Obesity, Metabolic Syndrome and Prediabetes: A Narrative Review (vol 10, pg 1995, 2019). DIABETES THERAPY, 10(6), 2023. doi:10.1007/s13300-019-00705-z
Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
Williams, S. M., Eleftheriadou, A., Alam, U., Cuthbertson, D. J., & Wilding, J. P. H. (2019). Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. DIABETES THERAPY, 10(6), 1995-2021. doi:10.1007/s13300-019-00693-0
SGLT2 inhibitors and urinary tract infections
Wilding, J. (2019). SGLT2 inhibitors and urinary tract infections. NATURE REVIEWS ENDOCRINOLOGY, 15(12), 687-688. doi:10.1038/s41574-019-0275-6
Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials
Kashiwagi, A., Shestakova, M. V., Ito, Y., Noguchi, M., Wilpshaar, W., Yoshida, S., & Wilding, J. P. H. (2019). Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. DIABETES THERAPY, 10(6), 2201-2217. doi:10.1007/s13300-019-00699-8
The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2019). The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides, 170208. doi:10.1016/j.peptides.2019.170208
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., . . . Sabatine, M. S. (2019). Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. CIRCULATION, 140(19), 1569-1577. doi:10.1161/CIRCULATIONAHA.119.042685
Semaglutide in weight management reply
Wilding, J. P. H. (2019). Semaglutide in weight management reply. LANCET, 394(10205), 1226-1227. doi:10.1016/S0140-6736(19)31904-X
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice
Ali, A., Bain, S., Hicks, D., Jones, P. N., Patel, D. C., Evans, M., . . . Wilding, J. (2019). SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. DIABETES THERAPY, 10(5), 1595-1622. doi:10.1007/s13300-019-0657-8
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice (vol 10, pg 1595, 2019)
Ali, A., Bain, S., Hicks, D., Jones, P. N., Patel, D. C., Evans, M., . . . Wilding, J. (2019). SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice (vol 10, pg 1595, 2019). DIABETES THERAPY, 10(5), 1623-1624. doi:10.1007/s13300-019-0670-y
Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus
Wilding, J. P. H., Rigney, U., Blak, B. T., Nolan, S. T., Fenici, P., & Medina, J. (2019). Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. DIABETES RESEARCH AND CLINICAL PRACTICE, 155. doi:10.1016/j.diabres.2019.107791
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., . . . Raz, I. (2019). Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7(8), 606-617. doi:10.1016/S2213-8587(19)30180-9
Should obesity be recognised as a disease?
Wilding, J. P. H., Mooney, V., & Pile, R. (2019). Should obesity be recognised as a disease?. BMJ-BRITISH MEDICAL JOURNAL, 366. doi:10.1136/bmj.l4258
Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARETIMI 58 Randomised, Placebo-Controlled Trial
Raz, I., Wiviott, S. D., Yanuv, I., Rozenberg, A., Zelniker, T. A., Cahn, A., . . . Mosenzon, O. (2019). Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARETIMI 58 Randomised, Placebo-Controlled Trial. In DIABETES Vol. 68. doi:10.2337/db19-244-OR
Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat.
Bowden Davies, K. A., Sprung, V. S., Norman, J. A., Thompson, A., Mitchell, K. L., Harrold, J. A., . . . Cuthbertson, D. J. (2019). Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat.. Medicine and science in sports and exercise, 51(6), 1169-1177. doi:10.1249/mss.0000000000001901
Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction
Uusinarkaus, K. T., Rodbard, H. W., Van Gaal, L., Wilding, J. P., Hansen, T., Sandberg, A., . . . Davies, M. J. (2019). Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction. In DIABETES Vol. 68. doi:10.2337/db19-1020-P
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019). Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. OBESITY REVIEWS, 20(6), 816-828. doi:10.1111/obr.12841
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., . . . Wiviott, S. D. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. In CIRCULATION Vol. 139 (pp. 2516-2527). doi:10.1161/CIRCULATIONAHA.119.039996
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., . . . Wiviott, S. D. (2019). Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. CIRCULATION, 139(22), 2528-2536. doi:10.1161/CIRCULATIONAHA.119.040130
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors
Brown, E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019). A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. DIABETES OBESITY & METABOLISM, 21, 9-18. doi:10.1111/dom.13650
Correction to: Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C.
Wong, S. P. Y., Huda, M., English, P., Bargiota, A., Wilding, J. P. H., Johnson, A., . . . Pinkney, J. H. (2019). Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C (vol 48, pg 2641, 2005). DIABETOLOGIA, 62(4), 732. doi:10.1007/s00125-019-4818-0
DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
de Mendonca Furtado, R. H., Bonaca, M., Raz, I., Zelniker, T., Mosenzon, O., Cahn, A., . . . Wiviott, S. (2019). DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL. Journal of the American College of Cardiology, 73(9), 1. doi:10.1016/s0735-1097(19)30610-2
Incorporating Patients' Perspectives into the Initial Stages of Core Outcome Set Development: A Rapid Review of Qualitative Studies of Type 2 Diabetes
Gorst, S. L., Young, B., Williamson, P. R., Wilding, J. P. H., & Harman, N. (2019). Incorporating Patients' Perspectives into the Initial Stages of Core Outcome Set Development: A Rapid Review of Qualitative Studies of Type 2 Diabetes. BMJ Open Diabetes Research and Care.
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., . . . Sabatine, M. S. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.. Circulation. doi:10.1161/circulationaha.118.038868
1,25(OH)(2)D-3 attenuates IL-6 and IL-1-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-B signaling pathways
Zhu, J., Bing, C., & Wilding, J. P. H. (2019). 1,25(OH)(2)D-3 attenuates IL-6 and IL-1-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-B signaling pathways. DIABETOLOGY & METABOLIC SYNDROME, 11. doi:10.1186/s13098-019-0405-2
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE, 380(4), 347-357. doi:10.1056/NEJMoa1812389
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., . . . Sabatine, M. S. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393(10166), 31-39. doi:10.1016/S0140-6736(18)32590-X
A Pragmatic Phase 4 Randomised Trial to evaluate the Effectiveness of Dapagliflozin compared to Standard of Care in patients with Type 2 Diabetes in Routine Primary Care (DECIDE: NCT02616666)
Williams, R., Beatty, S., Williamson, P., Fenici, P., Dodd, S., Medina, J., & Wilding, J. (2019). A Pragmatic Phase 4 Randomised Trial to evaluate the Effectiveness of Dapagliflozin compared to Standard of Care in patients with Type 2 Diabetes in Routine Primary Care (DECIDE: NCT02616666). In TRIALS Vol. 20. Retrieved from https://www.webofscience.com/
Change in categorical urinary albumin creatinine ratio in the DECLARE-TIMI 58 trial
Raz, I., Wiviott, S. D., Rozenberg, A., Zelniker, T. A., Cahn, A., Heerspink, H. J. L., . . . Mosenzon, O. (2019). Change in categorical urinary albumin creatinine ratio in the DECLARE-TIMI 58 trial. In DIABETOLOGIA Vol. 62 (pp. S330). Retrieved from https://www.webofscience.com/
DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?
McEwan, P., Bennett, H., Kartman, B., Edmonds, C., Gause-Nilsson, I., & Wilding, J. (2019). DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?. In VALUE IN HEALTH Vol. 22 (pp. S581). Retrieved from https://www.webofscience.com/
Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58
Furtado, R. H., Bonaca, M. P., Zelniker, T. A., Raz, I., Goodrich, E., Mosenzon, O., . . . Wiviott, S. (2019). Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/
Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
Zelniker, T. A., Bonaca, M. P., Mosenzon, O., Kuder, J. F., Murphy, S. A., Furtado, R. H., . . . Wiviott, S. D. (2019). Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. J. L., Cahn, A., . . . Wiviott, S. D. (2019). Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58. In EUROPEAN HEART JOURNAL Vol. 40 (pp. 54). Retrieved from https://www.webofscience.com/
Estimating healthcare resource implications associated with use of dapagliflozin: model predictions using data from the DECLARE-TIMI 58 trial
McEwan, P., Bennett, H., Kartman, B., Edmonds, C., Gause-Nilsson, I., & Wilding, J. (2019). Estimating healthcare resource implications associated with use of dapagliflozin: model predictions using data from the DECLARE-TIMI 58 trial. In DIABETOLOGIA Vol. 62 (pp. S396-S397). Retrieved from https://www.webofscience.com/
Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus
Berg, D., Wiviott, S., Scirica, B., Gurmu, Y., Mosenzon, O., Murphy, S., . . . Sabatine, M. (2019). Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus. In EUROPEAN HEART JOURNAL Vol. 40 (pp. 153). Retrieved from https://www.webofscience.com/
Metabolic health, rather than obesity status, contributes to endothelial dysfunction: a comparison of obesity/metabolic health related phenotypes
Sprung, V. S., Davies, K. A. B., Norman, J. A., Mitchell, K. L., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2019). Metabolic health, rather than obesity status, contributes to endothelial dysfunction: a comparison of obesity/metabolic health related phenotypes. In DIABETOLOGIA Vol. 62 (pp. S552). Retrieved from https://www.webofscience.com/
Obesity and Obstructive Sleep Apnea Syndrome
Seetho, I. W., & Wilding, J. P. H. (2019). Obesity and Obstructive Sleep Apnea Syndrome. In Endocrinology (pp. 243-271). Springer International Publishing. doi:10.1007/978-3-319-46933-1_24
Pooled cohort analysis of non-alcoholic fatty liver disease in patients with and without type 2 diabetes: time to take action
Brown, E., Sprung, V., Bowden-Davies, K., Wilton, M., Harrold, J., Rajeev, S., . . . Cuthbertson, D. J. (2019). Pooled cohort analysis of non-alcoholic fatty liver disease in patients with and without type 2 diabetes: time to take action. In DIABETOLOGIA Vol. 62 (pp. S536). Retrieved from https://www.webofscience.com/
Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
Zelniker, T. A., Morrow, D. A., Mosenzon, O., Goodrich, E., Murphy, S. A., Bhatt, D. L., . . . Wiviott, S. D. (2019). Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/
Safety and efficacy of dapagliflozin in the elderly: analysis from the DECLARE TIMI 58 study
Cahn, A., Wiviott, S. D., Mosenzon, O., Yanuv, I., Rozenberg, A., Murphy, S. A., . . . Raz, I. (2019). Safety and efficacy of dapagliflozin in the elderly: analysis from the DECLARE TIMI 58 study. In DIABETOLOGIA Vol. 62 (pp. S360). Retrieved from https://www.webofscience.com/
Severe insulin resistance and childhood obesity: A familial disorder in two siblings
Lim, J. Z., Mon, A., Brown, E., Alam, U., & Wilding, J. P. (2019). Severe insulin resistance and childhood obesity: A familial disorder in two siblings. In DIABETIC MEDICINE Vol. 36 (pp. 140). Retrieved from https://www.webofscience.com/
Short-term physical inactivity, with increased sedentary behaviour, causes a decline in endothelial function
Davies, K. A. B., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., Harrold, J. A., . . . Sprung, V. S. (2019). Short-term physical inactivity, with increased sedentary behaviour, causes a decline in endothelial function. In DIABETOLOGIA Vol. 62 (pp. S552). Retrieved from https://www.webofscience.com/
The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial
O'Donoghue, M. L., Kato, E. T., Mosenzon, O., Murphy, S. A., Cahn, A., Marmolejo, M. H., . . . Wiviott, S. D. (2019). The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial. In CIRCULATION Vol. 140. Retrieved from https://www.webofscience.com/
Therapeutic effect of improved glycaemic control with concomitant use of cannabis oil
Lim, J. Z., Abdelrahim, S., Alam, U., Wilding, J. P., & Mon, A. (2019). Therapeutic effect of improved glycaemic control with concomitant use of cannabis oil. In DIABETIC MEDICINE Vol. 36 (pp. 19-20). Retrieved from https://www.webofscience.com/
Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction
Wilding, J. P. H., Rodbard, H. W., Uusinarkaus, K. T., Van Gaal, L., Hansen, T., Sandberg, A. M. L., . . . Davies, M. J. (2019). Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction. In DIABETOLOGIA Vol. 62 (pp. S363-S364). Retrieved from https://www.webofscience.com/
2018
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
Shestakova, M. V., Wilding, J. P. H., Wilpshaar, W., Tretter, R., Orlova, V. L., & Verbovoy, A. F. (2018). A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. DIABETES RESEARCH AND CLINICAL PRACTICE, 146, 240-250. doi:10.1016/j.diabres.2018.10.018
Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management
Wilding, J., Zourikian, N., Di Minno, M., Khair, K., Marquardt, N., Benson, G., . . . Hermans, C. (2018). Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. OBESITY REVIEWS, 19(11), 1569-1584. doi:10.1111/obr.12746
Time for a new obesity narrative
Ralston, J., Brinsden, H., Buse, K., Candeias, V., Caterson, I., Hassell, T., . . . Woodward, E. (2018). Time for a new obesity narrative. LANCET, 392(10156), 1384-1386. doi:10.1016/S0140-6736(18)32537-6
Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography
Psarou, A., Cooper, H., & Wilding, J. P. H. (2018). Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. DIABETES THERAPY, 9(5), 1791-1810. doi:10.1007/s13300-018-0490-5
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
Wilding, J., Fernando, K., Milne, N., Evans, M., Ali, A., Bain, S., . . . Viljoen, A. (2018). SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. DIABETES THERAPY, 9(5), 1757-1773. doi:10.1007/s13300-018-0471-8
Vitamin D receptor ligands attenuate the inflammatory profile of IL-1 beta-stimulated human white preadipocytes via modulating the NF-kappa B and unfolded protein response pathways
Zhu, J., Bing, C., & Wilding, J. P. H. (2018). Vitamin D receptor ligands attenuate the inflammatory profile of IL-1β-stimulated human white preadipocytes via modulating the NF-κB and unfolded protein response pathways. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 503(2), 1049-1056. doi:10.1016/j.bbrc.2018.06.115
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Ahren, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., . . . Leiter, L. A. (2018). Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. DIABETES OBESITY & METABOLISM, 20(9), 2210-2219. doi:10.1111/dom.13353
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., . . . Wilding, J. P. H. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. LANCET, 392(10148), 637-649. doi:10.1016/S0140-6736(18)31773-2
Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set
Harman, N. L., Wilding, J., Curry, D., Harris, J., Logue, J., Pemberton, R. J., . . . Williamson, P. R. (2018). Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. TRIALS, 19. doi:10.1186/s13063-018-2805-2
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
Kosiborod, M., Birkeland, K. I., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., . . . Fenici, P. (2018). Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. DIABETES OBESITY & METABOLISM, 20(8), 1983-1987. doi:10.1111/dom.13299
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
Wilding, J., Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., . . . Medina, J. (2018). Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Medicine, 16. doi:10.1186/s12916-018-1085-8
A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin
Shestakova, M. V., Wilding, J. P., Wilpshaar, W., Tretter, R. N., Orlova, V. L., & Verbovoy, A. F. (2018). A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin. In DIABETES Vol. 67. doi:10.2337/db18-1131-P
Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-The Energize Study
Rajeev, S. P., Roberts, C. A., Cuthbertson, D. J., Sprung, V. S., Brown, E., Halford, J. C. J., . . . Wilding, J. P. (2018). Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-The Energize Study. In DIABETES Vol. 67. doi:10.2337/db18-1163-P
Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes
Wilding, J. P., Hockings, P., Johnsson, E. K., Maaske, J., Garcia-Sanchez, R., & Johansson, L. (2018). Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes. In DIABETES Vol. 67. doi:10.2337/db18-1175-P
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
Johanssoni, I., Hockings, P., Johnsson, E. K., Maaskes, J., Garcia-Sanchez, R., & Wilding, J. P. (2018). Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. In DIABETOLOGIA Vol. 61 (pp. S314). Retrieved from https://www.webofscience.com/
HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in UK Primary Care Patients with Type 2 Diabetes
Wilding, J. P., Rigney, U., Blak, B. T., Nolan, S. T., Fenici, P., & Medina, J. (2018). HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in UK Primary Care Patients with Type 2 Diabetes. In DIABETES Vol. 67. doi:10.2337/db18-1186-P
Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program
Rosenstock, J., Bantwal, G., Wilding, J. P., Dumas, R., Gonzalez-Galvez, G., Slee, A., . . . Matthews, D. R. (2018). Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. In DIABETES Vol. 67. doi:10.2337/db18-1191-P
Semaglutide treatment and renal function in the SUSTAIN 6 trial
Silver, R., Gumprecht, J., Vilsboll, T., Hansen, T., Pettersson, J., Vrazic, H., & Wilding, J. (2018). Semaglutide treatment and renal function in the SUSTAIN 6 trial. In DIABETOLOGIA Vol. 61 (pp. S40-S41). Retrieved from https://www.webofscience.com/
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study
Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J., . . . Magliano, D. (2018). Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. Journal of the American College of Cardiology, 71(23), 2628-2639. doi:10.1016/j.jacc.2018.03.009
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL
Cavender, M. A., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P., Khunti, K., . . . Kosiborod, M. (2018). SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 71(22), 2497-2506. doi:10.1016/j.jacc.2018.01.085
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK
Wilding, J. P. H. (2018). Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. CLINICAL OBESITY, 8(3), 211-225. doi:10.1111/cob.12248
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Thuresson, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., . . . Kosiborod, M. (2018). Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. DIABETES CARE, 41(6), E106-E108. doi:10.2337/dc18-0338
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
Nystrom, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2018). Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. DIABETES CARE, 41(6), E104-E105. doi:10.2337/dc18-0339
Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes
Bowden Davies, K. A., Sprung, V. S., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., . . . Cuthbertson, D. J. (2018). Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. Diabetologia, 61(6), 1282-1294. doi:10.1007/s00125-018-4603-5
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2018). The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. AMERICAN HEART JOURNAL, 200, 83-89. doi:10.1016/j.ahj.2018.01.012
Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome
Shillito, J. A., Lea, J., Tierney, S., Cleator, J., Tai, S., & Wilding, J. P. H. (2018). Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome. APPETITE, 125, 270-277. doi:10.1016/j.appet.2018.02.005
DECLARE-TIMI 58: Participants' baseline characteristics
Raz, I., Mosenzon, O., Bonaca, M. P., Cahn, A., Kato, E. T., Silverman, M. G., . . . Wiviott, S. D. (2018). DECLARE-TIMI 58: Participants' baseline characteristics. DIABETES OBESITY & METABOLISM, 20(5), 1102-1110. doi:10.1111/dom.13217
Metabolically healthy and unhealthy obesity: Metabolic health status rather than obesity is a more accurate prognostic marker for cardiovascular health
Sprung, V. S., Davies, K. A. B., Norman, J. A., Thompson, A., Wilding, J. P. H., Jones, H., . . . Cuthbertson, D. J. (2018). Metabolically healthy and unhealthy obesity: Metabolic health status rather than obesity is a more accurate prognostic marker for cardiovascular health. In DIABETIC MEDICINE Vol. 35 (pp. 53). Retrieved from https://www.webofscience.com/
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., . . . Fenici, P. (2018). Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". CIRCULATION, 137(9), 989-991. doi:10.1161/CIRCULATIONAHA.117.031847
Medication use for the treatment of diabetes in obese individuals
Wilding, J. P. H. (2018). Medication use for the treatment of diabetes in obese individuals. DIABETOLOGIA, 61(2), 265-272. doi:10.1007/s00125-017-4288-1
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E., Cuthbertson, D. J., & Wilding, J. P. (2018). Newer GLP-1 receptor agonists and obesity-diabetes. PEPTIDES, 100, 61-67. doi:10.1016/j.peptides.2017.12.009
A randomised, phase 2, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes
Wilding, J., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., . . . O'Neil, P. M. (2018). A randomised, phase 2, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes. In DIABETOLOGIA Vol. 61 (pp. S273-S274). Retrieved from https://www.webofscience.com/
A systematic review of electrophysiology in trials of pathogenetic treatments for diabetic peripheral neuropathy (DPN)
Nizza, J., Nelson, A. J., Petropoulos, I., Cuthbertson, D., Wilding, J. P., Malik, R., & Alam, U. (2018). A systematic review of electrophysiology in trials of pathogenetic treatments for diabetic peripheral neuropathy (DPN). In DIABETIC MEDICINE Vol. 35 (pp. 164). Retrieved from https://www.webofscience.com/
Age no impediment to effective weight loss with liraglutide 3.0mg: Data from two randomised trials
Wilding, J. P. H., Rubino, D. M., Kahan, S., Kushner, R., Jepsen, C. H., Smolarz, B. G., & Wyatt, H. (2018). Age no impediment to effective weight loss with liraglutide 3.0mg: Data from two randomised trials. In DIABETIC MEDICINE Vol. 35 (pp. 109-110). Retrieved from https://www.webofscience.com/
Clinical inertia: The patient's perspective in delays of Type 2 diabetes treatment(s)
Psarou, A., Wilding, J. P. H., & Cooper, H. (2018). Clinical inertia: The patient's perspective in delays of Type 2 diabetes treatment(s). In DIABETIC MEDICINE Vol. 35 (pp. 202). Retrieved from https://www.webofscience.com/
HbA<sub>1c</sub> changes in subjects with obesity without diabetes receiving semaglutide for weight management
Mosenzon, O., Wilding, J., Birkenfeld, A. L., McGowan, B., Pedersen, S. D., Wharton, S., . . . O'Neil, P. M. (2018). HbA<sub>1c</sub> changes in subjects with obesity without diabetes receiving semaglutide for weight management. In DIABETOLOGIA Vol. 61 (pp. S352-S353). Retrieved from https://www.webofscience.com/
High number of responders with pharmacotherapy-induced weight loss ≥15% in a placebo-controlled dose-ranging study of semaglutide in subjects with obesity
Birkenfeld, A. L., Wilding, J., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., . . . O'Neil, P. M. (2018). High number of responders with pharmacotherapy-induced weight loss ≥15% in a placebo-controlled dose-ranging study of semaglutide in subjects with obesity. In DIABETOLOGIA Vol. 61 (pp. S272-S273). Retrieved from https://www.webofscience.com/
Late-Breaking Clinical Trial: Novel Approaches to CV Prevention
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2018). Late-Breaking Clinical Trial: Novel Approaches to CV Prevention. In CIRCULATION Vol. 138 (pp. E754-E755). Retrieved from https://www.webofscience.com/
Metabolic decompensation and altered body composition after short-term physical inactivity in first-degree relatives of patients with Type 2 diabetes vs healthy controls
Davies, K. A. B., Sprung, V. S., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., . . . Cuthbertson, D. J. (2018). Metabolic decompensation and altered body composition after short-term physical inactivity in first-degree relatives of patients with Type 2 diabetes vs healthy controls. In DIABETIC MEDICINE Vol. 35 (pp. 31-32). Retrieved from https://www.webofscience.com/
Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs exenatide and dulaglutide in type 2 diabetes
Lingvay, I., de la Rosa, R., Marre, M., Nauck, M., Woo, V., Hansen, T., . . . Wilding, J. (2018). Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs exenatide and dulaglutide in type 2 diabetes. In DIABETOLOGIA Vol. 61 (pp. S375-S376). Retrieved from https://www.webofscience.com/
Relatively consistent effects of canagliflozin on outcomes regardless of baseline HbA<sub>1c</sub> in the CANVAS Program
Matthews, D. R., Rosenstock, J., Bantwal, G., Wilding, J., Dumas, R., Gonzalez-Galvez, G., . . . Fulcher, G. (2018). Relatively consistent effects of canagliflozin on outcomes regardless of baseline HbA<sub>1c</sub> in the CANVAS Program. In DIABETOLOGIA Vol. 61 (pp. S321). Retrieved from https://www.webofscience.com/
Type 2 diabetes individuals' perspectives and needs for improved healthcare in medication management
Psarou, A., Wilding, J. P. H., & Cooper, H. (2018). Type 2 diabetes individuals' perspectives and needs for improved healthcare in medication management. In DIABETIC MEDICINE Vol. 35 (pp. 201). Retrieved from https://www.webofscience.com/
2017
SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials
Harman, N. L., James, R., Wilding, J., & Williamson, P. R. (2017). SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials. TRIALS, 18. doi:10.1186/s13063-017-2317-5
Evaluation of Aintree LOSS, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement
Steele, T., Narayanan, R. P., James, M., James, J., Mazey, N., & Wilding, J. P. H. (2017). Evaluation of Aintree LOSS, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement. CLINICAL OBESITY, 7(6), 368-376. doi:10.1111/cob.12216
The impact of gastrointestinal adverse events on weight loss with semaglutide in subjects with type 2 diabetes
Atkin, S., Woo, V., de la Rosa, R., Wilding, J., Yamada, Y., Birch, S., . . . Ahren, B. (2017). The impact of gastrointestinal adverse events on weight loss with semaglutide in subjects with type 2 diabetes. In DIABETOLOGIA Vol. 60 (pp. S379-S380). Retrieved from https://www.webofscience.com/
Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction
Ashrafi, R., Modi, P., Oo, A. Y., Pullan, D. M., Jian, K., Zhang, H., . . . Wilding, J. P. H. (2017). Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction. EXPERIMENTAL PHYSIOLOGY, 102(11), 1424-1434. doi:10.1113/EP086412
Combination therapy for obesity
Wilding, J. P. H. (2017). Combination therapy for obesity. JOURNAL OF PSYCHOPHARMACOLOGY, 31(11), 1503-1508. doi:10.1177/0269881117737401
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., . . . Wilding, J. P. H. (2017). Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. DIABETES OBESITY & METABOLISM, 19(11), 1529-1536. doi:10.1111/dom.12963
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up
Wilding, J., Bailey, C., Rigney, U., Blak, B., Kok, M., & Emmas, C. (2017). Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. PRIMARY CARE DIABETES, 11(5), 437-444. doi:10.1016/j.pcd.2017.04.004
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
Petrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., . . . Colhoun, H. M. (2017). Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. LANCET DIABETES & ENDOCRINOLOGY, 5(8), 597-609. doi:10.1016/S2213-8587(17)30194-8
Screening methods for obstructive sleep apnoea in severely obese pregnant women
Longworth, H., McCallin, K., Narayanan, R. P., Turner, M. A., Quenby, S., Rycroft, D., . . . Wilding, J. P. H. (2017). Screening methods for obstructive sleep apnoea in severely obese pregnant women. CLINICAL OBESITY, 7(4), 239-244. doi:10.1111/cob.12196
Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
Bray, G. A., Kim, K. K., & Wilding, J. P. H. (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. OBESITY REVIEWS, 18(7), 715-723. doi:10.1111/obr.12551
OBSERVATIONAL STUDY ON THE EFFECTS OF IL-6 INHIBITOR THERAPY ON MYOSTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS
Chapman, M. J., Narayanan, R. P., Cross, A., Moots, R., Wilding, J., & Goodson, N. (2017). OBSERVATIONAL STUDY ON THE EFFECTS OF IL-6 INHIBITOR THERAPY ON MYOSTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS. In ANNALS OF THE RHEUMATIC DISEASES Vol. 76 (pp. 852). doi:10.1136/annrheumdis-2017-eular.5831
What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?
Cuthbertson, D., Steele, T., Wilding, J., Halford, J. C. G., Harrold, J. A., Hamer, M., & Karpe, F. (2017). What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?. International Journal of Obesity, 41, 853-865. doi:10.1038/ijo.2017.4
Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., . . . Fenici, P. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.. Circulation, 136(3), 249-259. doi:10.1161/circulationaha.117.029190
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Budoff, M. J., & Wilding, J. P. H. (2017). Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 71(5). doi:10.1111/ijcp.12948
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., . . . NN8022, S. C. A. L. E. O. P. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. LANCET, 389(10077), 1399-1409. doi:10.1016/S0140-6736(17)30069-7
Consensus recommendations on exploring effective solutions for the rising cost of diabetes
Sadikot, S. M., Das, A. K., Wilding, J., Siyan, A., Zargar, A. H., Saboo, B., . . . Kesavadev, J. (2017). Consensus recommendations on exploring effective solutions for the rising cost of diabetes. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 11(2), 141-147. doi:10.1016/j.dsx.2017.03.002
Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response
Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., . . . Cuthbertson, D. J. (2017). Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 312(3), E224-E233. doi:10.1152/ajpendo.00347.2016
Implementing a step reduction model to examine the metabolic effects of physical inactivity
Davies, K. A. B., Sprung, V. S., Norman, J. A., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2017). Implementing a step reduction model to examine the metabolic effects of physical inactivity. In DIABETIC MEDICINE Vol. 34 (pp. 58). Retrieved from https://www.webofscience.com/
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., . . . Ratner, R. E. (2017). Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. DIABETES, 66(2), 241-255. doi:10.2337/db16-0806
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: A randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)- study protocol
Rajeev, S., Sprung, V. S., Roberts, C., Harrold, J. A., Halford, J. C. G., Stancak, A., . . . Wilding, J. (2017). Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: A randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)- study protocol. BMJ Open, 7(1). doi:10.1136/bmjopen-2016-013539
Baseline characteristics of the DECLARE-TIMI 58 trial population
Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., . . . Wiviott, S. D. (2017). Baseline characteristics of the DECLARE-TIMI 58 trial population. In DIABETOLOGIA Vol. 60 (pp. S519-S520). Retrieved from https://www.webofscience.com/
Changes in HbA<sub>1c</sub> and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice
Wilding, J. P. H., Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., . . . Medina, J. (2017). Changes in HbA<sub>1c</sub> and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice. In DIABETOLOGIA Vol. 60 (pp. S301). Retrieved from https://www.webofscience.com/
DECLARE-TIMI 58: Design and Baseline Characteristics
Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., . . . Wiviott, S. D. (2017). DECLARE-TIMI 58: Design and Baseline Characteristics. In DIABETES Vol. 66 (pp. A333). Retrieved from https://www.webofscience.com/
Dapagliflozin in Renal Impairment: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit
Yadagiri, M., Bain, S. C., Robinson, T., Wilding, J. P. H., Pang, T., Mcgowan, B., . . . Ryder, R. E. J. (2017). Dapagliflozin in Renal Impairment: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit. In DIABETES Vol. 66 (pp. A45). Retrieved from https://www.webofscience.com/
Dapagliflozin therapy for Type 2 diabetes in primary care: effects on HbA1c, weight and blood pressure over two years follow-up
Wilding, J., Bailey, C., Rigney, U., Blak, B., Kok, M., & Emmas, C. (2017). Dapagliflozin therapy for Type 2 diabetes in primary care: effects on HbA1c, weight and blood pressure over two years follow-up. In DIABETIC MEDICINE Vol. 34 (pp. 189). Retrieved from https://www.webofscience.com/
Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes
Le Roux, C. W., Lau, D. C. W., Fujioka, K., Greenway, F., Wilding, J. P. H., Jacobsen, P. B., . . . Madsbad, S. (2017). Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes. In DIABETIC MEDICINE Vol. 34 (pp. 57). Retrieved from https://www.webofscience.com/
Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks
Le Roux, C., Bluher, M., Hermansen, K., Greenway, F., Fujioka, K., Donsmark, M., . . . Wilding, J. (2017). Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks. In BRITISH JOURNAL OF SURGERY Vol. 104 (pp. 14). Retrieved from https://www.webofscience.com/
Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease: CVD-REAL Study
Cavender, M. A., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P. H., Khunti, K., . . . Kosiborod, M. N. (2017). Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease: CVD-REAL Study. In DIABETES Vol. 66 (pp. A99-A100). Retrieved from https://www.webofscience.com/
Nutrition and Cardiometabolic Health
Bergeron, N., Siri-Tarino, P. W., Bray, G. A., & Krauss, R. M. (Eds.) (n.d.). Nutrition and Cardiometabolic Health. In . CRC Press. doi:10.1201/9781315119410
Pre-emptive diabetes medicines management to reduce first hypoglycaemic episodes facilitated by IT systems and nurse prescribing
Akiboye, F., Wilding, J., Wilson, S., Kerry, C., Round, R., & Rayman, G. (2017). Pre-emptive diabetes medicines management to reduce first hypoglycaemic episodes facilitated by IT systems and nurse prescribing. In DIABETIC MEDICINE Vol. 34 (pp. 143-144). Retrieved from https://www.webofscience.com/
The Merseyside and Greater Manchester regional genetic diabetes nursing service: increasing recognition of monogenic diabetes
Navein, P., Samad, S., Wilding, J., Hattersley, A., Colclough, K., & Shepherd, M. (2017). The Merseyside and Greater Manchester regional genetic diabetes nursing service: increasing recognition of monogenic diabetes. In DIABETIC MEDICINE Vol. 34 (pp. 181). Retrieved from https://www.webofscience.com/
The efficacy and safety of liraglutide 3.0mg for weight management are similar across baseline Edmonton Obesity Staging System (EOSS) categories: post-hoc analysis at 56 weeks
Wilding, J. P. H., Sharma, A. M., Finer, N., Padwal, R. S., Skjoth, T., Jensen, C. B., & Kushner, R. (2017). The efficacy and safety of liraglutide 3.0mg for weight management are similar across baseline Edmonton Obesity Staging System (EOSS) categories: post-hoc analysis at 56 weeks. In DIABETIC MEDICINE Vol. 34 (pp. 57). Retrieved from https://www.webofscience.com/
2016
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. (2016). GLP-1 as a target for therapeutic intervention. CURRENT OPINION IN PHARMACOLOGY, 31, 44-49. doi:10.1016/j.coph.2016.08.005
Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study
Wilding, J., Bailey, C., Rigney, U., Blak, B., Beekman, W., & Emmas, C. (2016). Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. DIABETES THERAPY, 7(4), 695-711. doi:10.1007/s13300-016-0193-8
Vitamin D3 analogues ZK159222 and Zk191784 have anti-inflammatory properties in human adipocytes
Bing, C., Ding, C., & Wilding, J. (2016). Vitamin D3 analogues ZK159222 and Zk191784 have anti-inflammatory properties in human adipocytes. Endocrinology, Metabolsim & Genetics. doi:10.15761/EMG.1000001
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
Fujioka, K., O'Neil, P. M., Davies, M., Greenway, F., Lau, D. C. W., Claudius, B., . . . Wilding, J. P. H. (2016). Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. OBESITY, 24(11), 2278-2288. doi:10.1002/oby.21629
Research update for articles published in EJCI in 2014
Maria Agra, R., Al-Daghri, N. M., Badimon, L., Bodi, V., Carbone, F., Chen, M., . . . Wilding, J. P. H. (2016). Research update for articles published in EJCI in 2014. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 46(10), 880-894. doi:10.1111/eci.12671
Greater weight loss and regression to normoglycaemia, and reduced risk of T2D, at 3 years in early weight loss responders to liraglutide 3.0 mg vs early non-responders
Wilding, J. P. H., Fujioka, K., Greenway, F., Lau, D. C. W., O'Neil, P., Jacobsen, P. B., . . . Madsbad, S. (2016). Greater weight loss and regression to normoglycaemia, and reduced risk of T2D, at 3 years in early weight loss responders to liraglutide 3.0 mg vs early non-responders. In DIABETOLOGIA Vol. 59 (pp. S330). Retrieved from https://www.webofscience.com/
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin
White, W. B., Wilson, C. A., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., . . . Zebrack, J. (2016). Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. HYPERTENSION, 68(3), 606-+. doi:10.1161/HYPERTENSIONAHA.116.07797
Set individualized targets for patients with type 2 diabetes.
Rajeev, S. P., & Wilding, J. (2016). Set individualized targets for patients with type 2 diabetes.. In The Practitioner Vol. 260 (pp. 23-26).
Weighing up dietary patterns Reply
Bray, G. A., Fruhbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016). Weighing up dietary patterns Reply. LANCET, 388(10046), 759-760. doi:10.1016/S0140-6736(16)31359-9
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016). Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. DIABETES CARE, 39, S154-S164. doi:10.2337/dcS15-3005
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial
White, W. B., Kupfer, S., Zannad, F., Mehta, C. R., Wilson, C. A., Lei, L., . . . Knapp, B. (2016). Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. DIABETES CARE, 39(7), 1267-1273. doi:10.2337/dc16-0303
Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira
Wilding, J. P. H., & Bain, S. C. (2016). Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. DIABETIC MEDICINE, 33(7), 864-876. doi:10.1111/dme.13021
Management of obesity
Bray, G. A., Fruhbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016). Management of obesity. LANCET, 387(10031), 1947-1956. doi:10.1016/S0140-6736(16)00271-3
Exposure-response analyses of liraglutide 3.0 mg for weight management
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016). Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 18(5), 491-499. doi:10.1111/dom.12639
SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
Wilding, J. (2016). SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?. LANCET DIABETES & ENDOCRINOLOGY, 4(5), 379-381. doi:10.1016/S2213-8587(16)00084-X
Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition
Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2016). Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. DIABETES OBESITY & METABOLISM, 18(2), 125-134. doi:10.1111/dom.12578
Fit for Birth - the effect of weight changes in obese pregnant women on maternal and neonatal outcomes: a pilot prospective cohort study
Narayanan, R. P., Weeks, A. D., Quenby, S., Rycroft, D., Hart, A., Longworth, H., . . . Wilding, J. P. H. (2016). Fit for Birth - the effect of weight changes in obese pregnant women on maternal and neonatal outcomes: a pilot prospective cohort study. CLINICAL OBESITY, 6(1), 79-88. doi:10.1111/cob.12129
Obesity and cardiovascular risk in type 2 diabetes
Whitmore, C., & Wilding, J. (2016). Obesity and cardiovascular risk in type 2 diabetes. In ADVANCED NUTRITION AND DIETETICS IN DIABETES (pp. 119-128). Retrieved from https://www.webofscience.com/
A baseline assessment of individuals with and without a family history of Type 2 diabetes: the effects of 14 day step reduction
Davies, K. A. B., Sprung, V. S., Norman, J. A., Wilding, J. P., Kemp, G. J., & Cuthbertson, D. J. (2016). A baseline assessment of individuals with and without a family history of Type 2 diabetes: the effects of 14 day step reduction. In DIABETIC MEDICINE Vol. 33 (pp. 74). Retrieved from https://www.webofscience.com/
A rare case of PICA syndrome post bariatric-surgery
Rajeev, S. P., McQuaid, P., Cowell, A., & Wilding, J. (2016). A rare case of PICA syndrome post bariatric-surgery. In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 9). Retrieved from https://www.webofscience.com/
Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis
Ashrafi, R., Yon, M., Pickavance, L., Gerges, J. Y., Davis, G., Wilding, J., . . . Boyett, M. (2016). Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis. JOURNAL OF OBESITY, 2016. doi:10.1155/2016/7127898
Characteristics of Individuals Developing Type 2 Diabetes in the SCALE Obesity and Prediabetes Randomized, Double-Blind, Liraglutide vs. Placebo Trial
Lau, D. C. W., Blueher, M., Van Gaal, L., Rubino, D. M., Guerrero, G., Manning, L. S., & Wilding, J. P. H. (2016). Characteristics of Individuals Developing Type 2 Diabetes in the SCALE Obesity and Prediabetes Randomized, Double-Blind, Liraglutide vs. Placebo Trial. In DIABETES Vol. 65 (pp. A510). Retrieved from https://www.webofscience.com/
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years. Diabetes Obes Metab
Wilding, J. P. H. (2016). Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years. Diabetes Obes Metab. Therapeutic Research, 37(4), 386-387.
Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes? The Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit
Yadagiri, M., Sen Gupta, P., Stephens, J. W., Robinson, A., Phylactou, M., Kennedy, A., . . . Ryder, R. E. J. (2016). Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes? The Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit. In DIABETIC MEDICINE Vol. 33 (pp. 30-31). Retrieved from https://www.webofscience.com/
Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks
Wilding, J. P. H., Hermansen, K., Greenway, F., Fujioka, K., Donsmark, M., Nzeakor, N., & Blueher, M. (2016). Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks. DIABETIC MEDICINE, 33, 83. Retrieved from https://www.webofscience.com/
Increased self-efficacy in taking Type 2 diabetes medicines can improve adherence
Psarou, A., Wilding, J. H. P., & Cooper, H. (2016). Increased self-efficacy in taking Type 2 diabetes medicines can improve adherence. In DIABETIC MEDICINE Vol. 33 (pp. 190). Retrieved from https://www.webofscience.com/
Surgical cancellation rates in people with diabetes: passport to surgery
Akiboye, F., Page, E., Gardener, H., Wilding, J., & Rayman, G. (2016). Surgical cancellation rates in people with diabetes: passport to surgery. In DIABETIC MEDICINE Vol. 33 (pp. 182-183). Retrieved from https://www.webofscience.com/
The Glycemic Response to Dapagliflozin According to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit
Thong, K. Y., Yadagiri, M., Sen Gupta, P., Winocour, P., Joshi, M., Wilding, J., . . . Ryder, R. E. J. (2016). The Glycemic Response to Dapagliflozin According to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit. In DIABETES Vol. 65 (pp. A307). Retrieved from https://www.webofscience.com/
2015
Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea
Seetho, I. W., Asher, R., Parker, R. J., Craig, S., Duffy, N., Hardy, K. J., & Wilding, J. P. H. (2015). Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea. SLEEP AND BREATHING, 19(4), 1155-1165. doi:10.1007/s11325-015-1131-0
Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study
Steele, C. A., Powell, J., Kemp, G., Halford, J., Wilding, J., Harrold, J., . . . Daousi, C. (2015). Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study. International Journal of Obesity, 39, 1376-1382. doi:10.1038/ijo.2015.82
Serum urate and obstructive sleep apnoea in severe obesity
Seetho, I., Parker, R. J., Craig, S., Duffy, N., Hardy, K., Wilding, J., & Goodson, N. (2015). Serum urate and obstructive sleep apnoea in severe obesity. Chronic Respiratory Disease, 12(03), 238-246. doi:10.1177/1479972315586197
Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment
Seetho, I. W., Ramírez-Torres, A., Albalat, A., Mullen, W., Mischak, H., Parker, R. J., . . . Wilding, J. P. (2015). Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment. Sleep Science, 8(2), 58-67. doi:10.1016/j.slsci.2015.06.004
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., . . . NN, S. O. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. doi:10.1056/NEJMoa1411892
Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes
Cefalu, W. T., Stenlof, K., Leiter, L. A., Wilding, J. P. H., Blonde, L., Polidori, D., . . . Meininger, G. (2020). Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes. Diabetologia, 58(6), 1183-1187. doi:10.1007/s00125-015-3547-2
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., . . . Knapp, B. (2015). Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. LANCET, 385(9982), 2067-2076. doi:10.1016/S0140-6736(14)62225-X
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., . . . Pfeffer, M. A. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. AMERICAN HEART JOURNAL, 169(5), 631-U75. doi:10.1016/j.ahj.2015.02.002
Efficacy and safety of canagliflozin by baseline HbA(1c) and known duration of type 2 diabetes mellitus
Wilding, J. P. H., Blonde, L., Leiter, L. A., Cerdas, S., Tong, C., Yee, J., & Meininger, G. (2015). Efficacy and safety of canagliflozin by baseline HbA(1c) and known duration of type 2 diabetes mellitus. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 29(3), 438-444. doi:10.1016/j.jdiacomp.2014.12.016
Impact of bariatric surgery on physical functioning in obese adults
Steele, T., Cuthbertson, D. J., & Wilding, J. P. H. (2015). Impact of bariatric surgery on physical functioning in obese adults. OBESITY REVIEWS, 16(3), 248-258. doi:10.1111/obr.12247
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time
Parikh, S., Wilding, J., Jabbour, S., & Hardy, E. (2015). Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 69(2), 186-198. doi:10.1111/ijcp.12531
Pathophysiology and aetiology of obesity
Baqai, N., & Wilding, J. P. H. (2015). Pathophysiology and aetiology of obesity. Medicine, 43(2), 73-76. doi:10.1016/j.mpmed.2014.11.016
An observation of gestational weight gain in obese pregnancies
Abayomi, J. C., Charnley, M. S., Weeks, A., & Wilding, J. P. H. (2015). An observation of gestational weight gain in obese pregnancies. PROCEEDINGS OF THE NUTRITION SOCIETY, 74(OCE4), E255. doi:10.1017/S0029665115002979
Changes in HbA<sub>1c</sub> and weight in type 2 diabetes patients initiating dapagliflozin treatment in routine UK primary care
Wilding, J. P. H., Bailey, C. J., Rigney, U., Blak, B., Beekman, W., & Emmas, C. E. (2015). Changes in HbA<sub>1c</sub> and weight in type 2 diabetes patients initiating dapagliflozin treatment in routine UK primary care. In DIABETOLOGIA Vol. 58 (pp. S352-S353). Retrieved from https://www.webofscience.com/
Early Weight Loss Responders to Liraglutide 3.0 mg in the SCALE Obesity and Prediabetes Trial Achieve Greater Reversal of Prediabetes than Placebo
Wilding, J. P. H., Blueher, M., Hermansen, K., Greenway, F., Fujioka, K., Claudius, B., . . . Lau, D. C. W. (2015). Early Weight Loss Responders to Liraglutide 3.0 mg in the SCALE Obesity and Prediabetes Trial Achieve Greater Reversal of Prediabetes than Placebo. In DIABETES Vol. 64 (pp. A568). Retrieved from https://www.webofscience.com/
Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks
Blueher, M., Hermansen, K., Greenway, F., Fujioka, K., Donsmark, M., Jensen, C. B., & Wilding, J. P. H. (2015). Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. In DIABETOLOGIA Vol. 58 (pp. S310). Retrieved from https://www.webofscience.com/
In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of Type 2 diabetes: SCALE obesity and pre-diabetes trial
Wilding, J., Astrup, A., Fujioka, K., Greenway, F., Krempf, M., Lau, D., . . . Violante Ortiz, R. (2015). In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of Type 2 diabetes: SCALE obesity and pre-diabetes trial. In DIABETIC MEDICINE Vol. 32 (pp. 71). Retrieved from https://www.webofscience.com/
Managing patients with type 2 diabetes and obesity.
Wilding, J. (2015). Managing patients with type 2 diabetes and obesity.. The Practitioner, 259(1778), 25-3.
Obesity as a disability: a weighty precedent?
Khan, M., Clift, A. K., O'Cinneide, C., & Wilding, J. (2015). Obesity as a disability: a weighty precedent?. CLINICAL OBESITY, 5(4), 163-164. doi:10.1111/cob.12102
Optimising clinical care in diabetes through research: a partnership with primary care
Navein, P., & Wilding, J. P. H. (2015). Optimising clinical care in diabetes through research: a partnership with primary care. DIABETIC MEDICINE, 32, 197-198. Retrieved from https://www.webofscience.com/
SGLT2 inhibition and ketoacidosis - should we be concerned?
Rajeev, S. P., & Wilding, J. P. H. (2015). SGLT2 inhibition and ketoacidosis - should we be concerned?. BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE, 15(4), 155-158. doi:10.15277/bjdvd.2015.047
Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial
Wilding, J., Lau, D., Astrup, A., Fujioka, K., Greenway, F., Krempf, M., . . . Pi-Sunyer, X. (2015). Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial. In DIABETIC MEDICINE Vol. 32 (pp. 70). Retrieved from https://www.webofscience.com/
Serum Adiponectin Determines Circulating Vitamin D Concentration Independently of Other Adipokines
Narayanan, R. P., Boyle, L. D., Ng, S., Kahlon, A., Cross, A., Ding, C., . . . Wilding, J. P. H. (2015). Serum Adiponectin Determines Circulating Vitamin D Concentration Independently of Other Adipokines. In DIABETES Vol. 64 (pp. A574). Retrieved from https://www.webofscience.com/
2014
Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle
Cuthbertson, D. J., Irwin, A., Sprung, V. S., Jones, H., Pugh, C. J. A., Daousi, C., . . . Kemp, G. J. (2014). Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. CLINICAL SCIENCE, 127(11-12), 655-663. doi:10.1042/CS20130404
Liraglutide 3.0 Mg Improves Body Weight and Cardiometabolic Risk Factors in Overweight or Obese Adults without Diabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial
Le Roux, C., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Pi-Sunyer, F. X. (2014). Liraglutide 3.0 Mg Improves Body Weight and Cardiometabolic Risk Factors in Overweight or Obese Adults without Diabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/
Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity
Seetho, I. W., Parker, R. J., Craig, S., Duffy, N., Hardy, K. J., & Wilding, J. P. H. (2014). Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity. JOURNAL OF SLEEP RESEARCH, 23(6), 700-708. doi:10.1111/jsr.12156
GUIDELINES Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance
Stegenga, H., Haines, A., Jones, K., & Wilding, J. (2014). GUIDELINES Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. BMJ-BRITISH MEDICAL JOURNAL, 349. doi:10.1136/bmj.g6608
Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome
Seetho, I. W., & Wilding, J. P. H. (2014). Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. CHRONIC RESPIRATORY DISEASE, 11(4), 257-275. doi:10.1177/1479972314552806
A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes
Boyle, L. D., & Wilding, J. P. H. (2014). A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. EXPERT OPINION ON DRUG SAFETY, 13(11), 1535-1544. doi:10.1517/14740338.2014.959488
Urinary proteomics in obstructive sleep apnoea and obesity
Seetho, I. W., Siwy, J., Albalat, A., Mullen, W., Mischak, H., Parker, R. J., . . . Wilding, J. P. H. (2014). Urinary proteomics in obstructive sleep apnoea and obesity. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 44(11), 1104-1115. doi:10.1111/eci.12346
Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle
Irwin, A. (2014, October 1). Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. (Master's Thesis, University of Liverpool).
The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
Wilding, J. P. H. (2014). The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. METABOLISM-CLINICAL AND EXPERIMENTAL, 63(10), 1228-1237. doi:10.1016/j.metabol.2014.06.018
Glucose metabolism and the pathophysiology of diabetes mellitus
Wile, D. B., & Wilding, J. P. H. (2014). Glucose metabolism and the pathophysiology of diabetes mellitus. In Clinical Biochemistry: Metabolic and Clinical Aspects (pp. 273-304). Elsevier. doi:10.1016/b978-0-7020-5140-1.00015-8
The clinical management of diabetes mellitus
Seetho, I. W., & Wilding, J. P. H. (2014). The clinical management of diabetes mellitus. In Clinical Biochemistry: Metabolic and Clinical Aspects (pp. 305-332). Elsevier. doi:10.1016/b978-0-7020-5140-1.00016-x
CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL
White, W. B., Kupfer, S., Nissen, S., Cushman, W., Bakris, G., Heller, S., . . . Cannon, C. (2014). CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 63 (pp. A116). doi:10.1016/S0735-1097(14)60116-9
Characteristics and perspectives of night-eating behaviour in a severely obese population.
Cleator, J., Judd, P., James, M., Abbott, J., Sutton, C. J., & Wilding, J. P. H. (2014). Characteristics and perspectives of night-eating behaviour in a severely obese population.. Clinical obesity, 4(1), 30-38. doi:10.1111/cob.12037
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
Bolinder, J., Ljunggren, O., Johansson, L., Wilding, J., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2014). Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism, 16(2), 159-169. doi:10.1111/dom.12189
Effect of a Cooked Meat Meal on Serum Creatinine and Estimated Glomerular Filtration Rate in Diabetes-Related Kidney Disease
Nair, S., O'Brien, S. V., Hayden, K., Pandya, B., Lisboa, P. J. G., Hardy, K. J., & Wilding, J. P. H. (2014). Effect of a Cooked Meat Meal on Serum Creatinine and Estimated Glomerular Filtration Rate in Diabetes-Related Kidney Disease. Diabetes Care, 37(2), 483-487. doi:10.2337/dc13-1770
1,25-dihydroxyvitamin D3 inhibits macrophage-induced inflammatory response in human adipocytes via NF-κB and MAPK pathways
Ding, C., Bing, C., & Wilding, J. P. (2014). 1,25-dihydroxyvitamin D3 inhibits macrophage-induced inflammatory response in human adipocytes via NF-κB and MAPK pathways. In FEBS JOURNAL Vol. 281 (pp. 86). Retrieved from https://www.webofscience.com/
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., . . . Guimaraes, A. E. (2014). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. Austrian Journal of Clinical Endocrinology and Metabolism, 7(2), 77.
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
Wilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & Dapagliflozin 006 Study Group. (2014). Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 16(2), 124-136. doi:10.1111/dom.12187
Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial
Fujioka, K., Wilding, J. P. H., Astrup, A., Greenway, F., Halpern, A., Krempf, M., . . . Pi-Sunyer, X. (2014). Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. DIABETOLOGIA, 57, S368-S369. Retrieved from https://www.webofscience.com/
Glycaemic efficacy of canaglilozin by baseline HbA1c and known duration of type 2 diabetes mellitus
Cerdas, S., Leiter, L. A., Blonde, L., Wilding, J., Tong, C., Yee, J., & Meininger, G. (2014). Glycaemic efficacy of canaglilozin by baseline HbA1c and known duration of type 2 diabetes mellitus. In DIABETOLOGIA Vol. 57 (pp. S344). Retrieved from https://www.webofscience.com/
Liraglutide 3.0 Mg Improves Insulin Secretion and Action in Overweight and Obese Adults without Diabetes: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial
Wilding, J., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Pi-Sunyer, F. X. (2014). Liraglutide 3.0 Mg Improves Insulin Secretion and Action in Overweight and Obese Adults without Diabetes: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/
Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial
Pi-Sunyer, F. X., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Wilding, J. (2014). Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/
Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial
Pi-Sunyer, F. X., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Wilding, J. (2014). Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/
Liraglutide 3.0 mg improves insulin secretion and action in overweight/obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial
Lau, D. C. W., Wilding, J. P. H., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., . . . Pi-Sunyer, X. (2014). Liraglutide 3.0 mg improves insulin secretion and action in overweight/obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. DIABETOLOGIA, 57, S358. Retrieved from https://www.webofscience.com/
Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial
Krempf, M., Astrup, A., le Roux, C., Fujioka, K., Greenway, F., Halpern, A., . . . Pi-Sunyer, X. (2014). Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. DIABETOLOGIA, 57, S368. Retrieved from https://www.webofscience.com/
Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial
Pi-Sunyer, X., Fujioka, K., le Roux, C., Astrup, A., Greenway, F., Halpern, A., . . . Wilding, J. P. H. (2014). Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. DIABETOLOGIA, 57, S37. Retrieved from https://www.webofscience.com/
Liraglutide in the treatment of obesity
Ng, S. Y. A., & Wilding, J. P. H. (2014). Liraglutide in the treatment of obesity. EXPERT OPINION ON BIOLOGICAL THERAPY, 14(8), 1215-1224. doi:10.1517/14712598.2014.925870
Obstructive sleep apnoea in diabetes - assessment and awareness
Seetho, I. W., O’Brien, S. V., Hardy, K. J., & Wilding, J. P. H. (n.d.). Obstructive sleep apnoea in diabetes - assessment and awareness. British Journal of Diabetes, 14(3), 105. doi:10.15277/bjdvd.2014.025
Safety and Tolerability of Liraglutide 3.0 Mg in Overweight and Obese Adults: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial
Lau, D. C., Astrup, A., Fujioka, K., Greenway, F. L., Halpern, A., Krempf, M., . . . Pi-Sunyer, F. X. (2014). Safety and Tolerability of Liraglutide 3.0 Mg in Overweight and Obese Adults: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial. In ENDOCRINE REVIEWS Vol. 35. Retrieved from https://www.webofscience.com/
Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial
le Roux, C., Lau, D. C. W., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., . . . Pi-Sunyer, X. (2014). Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. DIABETOLOGIA, 57, S338. Retrieved from https://www.webofscience.com/
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014). The importance of weight management in type 2 diabetes mellitus. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 68(6), 682-691. doi:10.1111/ijcp.12384
URATE IS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNOEA IN OBESE WOMEN
Seetho, I. W., Ahmad, A., Parker, R. J., Craig, S., Duffy, N., Hardy, K. J., . . . Goodson, N. (2014). URATE IS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNOEA IN OBESE WOMEN. In RHEUMATOLOGY Vol. 53 (pp. 163). Retrieved from https://www.webofscience.com/
2013
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
Wilding, J. P. H., Charpentier, G., Hollander, P., Gonzalez-Galvez, G., Mathieu, C., Vercruysse, F., . . . Meininger, G. (2013). Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 67(12), 1267-1282. doi:10.1111/ijcp.12322
Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population
Cleator, J., Abbott, J., Judd, P., Wilding, J. P. H., & Sutton, C. J. (2013). Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population. SLEEP MEDICINE, 14(11), 1151-1156. doi:10.1016/j.sleep.2013.04.026
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., . . . Knapp, B. (2013). Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE, 369(14), 1327-1335. doi:10.1056/NEJMoa1305889
Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms
Chiasson, J. -L., Wilding, J., Blonde, L., Polidori, D., Meininger, G., & Stein, P. (2013). Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms. Canadian Journal of Diabetes, 37, S29. doi:10.1016/j.jcjd.2013.08.086
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
Boyle, L. D., & Wilding, J. P. H. (2013). Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. EXPERT OPINION ON EMERGING DRUGS, 18(3), 375-391. doi:10.1517/14728214.2013.831405
How to approach endocrine assessment in severe obesity?
Seetho, I. W., & Wilding, J. P. H. (2013). How to approach endocrine assessment in severe obesity?. CLINICAL ENDOCRINOLOGY, 79(2), 163-167. doi:10.1111/cen.12256
Screening for obstructive sleep apnoea in obesity and diabetes potential for future approaches
Seetho, I. W., & Wilding, J. P. H. (2013). Screening for obstructive sleep apnoea in obesity and diabetes potential for future approaches. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 43(6), 640-655. doi:10.1111/eci.12083
Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?
Daousi, C., Pinkney, J. H., Cleator, J., Wilding, J. P., & Ranganath, L. R. (2013). Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?. REGULATORY PEPTIDES, 183, 54-61. doi:10.1016/j.regpep.2013.03.004
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
Fonseca, V. A., Ferrannini, E., Wilding, J. P., Wilpshaar, W., Dhanjal, P., Ball, G., & Klasen, S. (2013). Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 27(3), 268-273. doi:10.1016/j.jdiacomp.2012.11.005
DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENSOIS WITH A NORMAL EJECTION FRACTION
Ashrafi, R., Gerges, J. Y., Hart, G., Boyett, M., Davis, G., & Wilding, J. (2013). DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENSOIS WITH A NORMAL EJECTION FRACTION. HEART, 99, A125. doi:10.1136/heartjnl-2013-304019.232
Orlistat: should we worry about liver inflammation?
Wilding, J. (2013). Orlistat: should we worry about liver inflammation?. BMJ-BRITISH MEDICAL JOURNAL, 346. doi:10.1136/bmj.f2777
1,25-dihydroxyvitamin D<sub>3</sub> Protects against Macrophage-Induced Activation of NFκB and MAPK Signalling and Chemokine Release in Human Adipocytes
Ding, C., Wilding, J. P. H., & Bing, C. (2013). 1,25-dihydroxyvitamin D<sub>3</sub> Protects against Macrophage-Induced Activation of NFκB and MAPK Signalling and Chemokine Release in Human Adipocytes. PLOS ONE, 8(4). doi:10.1371/journal.pone.0061707
Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic
Steele, C. A., Cuthbertson, D. J., MacFarlane, I. A., Javadpour, M., Das, K. S. V., Gilkes, C., . . . Daousi, C. (2013). Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 168(4), 501-507. doi:10.1530/EJE-12-0792
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., & Parikh, S. (2013). Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 138, S27-S38. doi:10.1055/s-0032-1305284
Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms
Blonde, L., Wilding, J., Chiasson, J. -L., Polidori, D., Meininger, G., & Stein, P. (2013). Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms. In DIABETES Vol. 62 (pp. A288). Retrieved from https://www.webofscience.com/
Canagliflozin lowers HbA<sub>1c</sub> and blood pressure through weight loss-independent and weight loss-associated mechanisms
Wilding, J., Blonde, L., Chiasson, J. -L., Polidori, D., Meininger, G., & Stein, P. (2013). Canagliflozin lowers HbA<sub>1c</sub> and blood pressure through weight loss-independent and weight loss-associated mechanisms. In DIABETOLOGIA Vol. 56 (pp. S379). Retrieved from https://www.webofscience.com/
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
Wilding, J. P. H., Leonsson-Zachrisson, M., Wessman, C., & Johnsson, E. (2013). Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. DIABETES OBESITY & METABOLISM, 15(8), 750-759. doi:10.1111/dom.12088
Effect of Cooked Meat Meal on Creatinine and eGFR in Diabetes Related Kidney Disease
Nair, S., O'Brien, S., Hardy, K. J., & Wilding, J. P. (2013). Effect of Cooked Meat Meal on Creatinine and eGFR in Diabetes Related Kidney Disease. In DIABETES Vol. 62 (pp. A136). Retrieved from https://www.webofscience.com/
Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus inadequately controlled with metformin plus sulphonylurea over 52 weeks
Vercruysse, F., Charpentier, G., Wilding, J., Hollander, P., Gonzalez Galvez, G., Mathieu, C., . . . Meininger, G. (2013). Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus inadequately controlled with metformin plus sulphonylurea over 52 weeks. In DIABETOLOGIA Vol. 56 (pp. S373). Retrieved from https://www.webofscience.com/
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., & Houzer, A. (2013). Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. DIABETES OBESITY & METABOLISM, 15(5), 403-409. doi:10.1111/dom.12038
Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged
Huda, M. S. B., Mani, H., Durham, B. H., Dovey, T. M., Halford, J. C. G., Aditya, B. S., . . . Hart, I. K. (2013). Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. ENDOCRINE, 43(3), 696-704. doi:10.1007/s12020-012-9838-1
Vitamin D reduces cytokine-induced insulin resistance in human adipocytes
Wilding-Steele, T. P., Ding, C., Madi, M., Bing, C., & Wilding, J. P. H. (2013). Vitamin D reduces cytokine-induced insulin resistance in human adipocytes. DIABETIC MEDICINE, 30, 40. Retrieved from https://www.webofscience.com/
2012
Vitamin D signalling in adipose tissue
Ding, C., Gao, D., Wilding, J., Trayhurn, P., & Bing, C. (2012). Vitamin D signalling in adipose tissue. BRITISH JOURNAL OF NUTRITION, 108(11), 1915-1923. doi:10.1017/S0007114512003285
A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus
Thondam, S. K., Cuthbertson, D. J., Aditya, B. S., MacFarlane, I. A., Wilding, J. P., & Daousi, C. (2012). A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. CLINICAL ENDOCRINOLOGY, 77(4), 635-637. doi:10.1111/j.1365-2265.2012.04368.x
Are the causes of obesity primarily environmental? Yes
Wilding, J. (2012). Are the causes of obesity primarily environmental? Yes. BMJ-BRITISH MEDICAL JOURNAL, 345. doi:10.1136/bmj.e5843
Night eating syndrome: implications for severe obesity
Cleator, J., Abbott, J., Judd, P., Sutton, C., & Wilding, J. P. H. (2012). Night eating syndrome: implications for severe obesity. NUTRITION & DIABETES, 2. doi:10.1038/nutd.2012.16
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschoep, M. H., & Wilding, J. P. H. (2012). Anti-obesity drugs: past, present and future. DISEASE MODELS & MECHANISMS, 5(5), 621-626. doi:10.1242/dmm.009621
Facing the Challenges for Europe - Research into Action: Liverpool European Congress of Obesity, May 12-15, 2013
Wilding, J. P. H., & Halford, J. C. G. (2012). Facing the Challenges for Europe - Research into Action: Liverpool European Congress of Obesity, May 12-15, 2013. OBESITY FACTS, 5(4), 629-634. doi:10.1159/000342705
Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus
Thondam, S. K., Cross, A., Cuthbertson, D. J., Wilding, J. P., & Daousi, C. (2012). Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. DIABETIC MEDICINE, 29(8), E205-E210. doi:10.1111/j.1464-5491.2012.03675.x
Response to Monesi <i>et al</i>. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study
Nair, S., Hardy, K. J., & Wilding, J. P. H. (2012). Response to Monesi <i>et al</i>. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. DIABETIC MEDICINE, 29(8), 1086-1087. doi:10.1111/j.1464-5491.2012.03569.x
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., & Parikh, S. (2012). Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial. ANNALS OF INTERNAL MEDICINE, 156(6), 405-U50. doi:10.7326/0003-4819-156-6-201203200-00003
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Bolinder, J., Ljunggren, O., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., . . . Parikh, S. (2012). Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 97(3), 1020-1031. doi:10.1210/jc.2011-2260
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., . . . Parikh, S. (2012). Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. The Journal of Clinical Endocrinology & Metabolism, 97(3), 1020-1031. doi:10.1210/jc.2011-2260
Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 Inhibitor, Improves Glycemic Control and Reduces Body Weight in Subjects With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin (MET) and Sulfonylurea (SU)
Wilding, J., Mathieu, C., Vercruysse, F., Usiskin, K., Deng, L., & Canovatchel, W. (2012). Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 Inhibitor, Improves Glycemic Control and Reduces Body Weight in Subjects With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin (MET) and Sulfonylurea (SU). In DIABETES Vol. 61 (pp. A262). Retrieved from https://www.webofscience.com/
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea
Wilding, J., Mathieu, C., Deng, L., Black, S., Vercruysse, F., Canovatchel, W., & Meininger, G. (2012). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea. In DIABETOLOGIA Vol. 55 (pp. S315-S316). Retrieved from https://www.webofscience.com/
Chronic non-communicable diseases: adding weight to evidence
Purcell, H., Day, C., Ziso, B., Wilding, J., & Daly, C. (2012). Chronic non-communicable diseases: adding weight to evidence. In H. Purcell (Ed.), Chronic non-communicable diseases (pp. 1-12). London: NHSI.
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
Ljunggren, O., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2012). Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. DIABETES OBESITY & METABOLISM, 14(11), 990-999. doi:10.1111/j.1463-1326.2012.01630.x
Dapagliflozin has no long-term effect on markers of bone turnover or bone mineral density in patients with inadequately controlled type 2 diabetes on metformin
Ljunggren, O., Bolinder, J., Johansson, L., Wilding, J. P. H., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2012). Dapagliflozin has no long-term effect on markers of bone turnover or bone mineral density in patients with inadequately controlled type 2 diabetes on metformin. In DIABETOLOGIA Vol. 55 (pp. S306-S307). Retrieved from https://www.webofscience.com/
Dapagliflozin produces long-term reductions in body weight, waist circumference and total fat mass in patients with type 2 diabetes inadequately controlled on metformin
Bolinder, J., Ljunggren, O., Johansson, L., Wilding, J. P. H., Langkilde, A. M., Sjostrom, C. D., . . . Parikh, S. (2012). Dapagliflozin produces long-term reductions in body weight, waist circumference and total fat mass in patients with type 2 diabetes inadequately controlled on metformin. In DIABETOLOGIA Vol. 55 (pp. S308). Retrieved from https://www.webofscience.com/
Facing the Challenges for Europe Research into Action: Liverpool European Congress of Obesity, May 1215, 2013
Wilding, J. P. H., & Halford, J. C. G. (2012). Facing the Challenges for Europe Research into Action: Liverpool European Congress of Obesity, May 1215, 2013. Obesity Facts, 5(4), 629-634. doi:10.1159/000342705
High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat
Ashrafi, R., Yon, M. A., Yanni-Gerges, J., Hart, G., Boyett, M., Davis, G. K., . . . Wilding, J. P. H. (2012). High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat. In PROCEEDINGS OF THE NUTRITION SOCIETY Vol. 71 (pp. E242). doi:10.1017/S0029665112003333
High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat
Ashrafi, R., Yon, M. A., Yanni-Gerges, J., Hart, G., Boyett, M., Davis, G. K., . . . Wilding, J. P. H. (2012). High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat. In Joint Winter Meeting 2012 (pp. ?). London: Cambridge University Press.
Long-Term Effectiveness of Dapagliflozin Over 104 Weeks in Patients With Type 2 Diabetes Poorly Controlled With Insulin
Wilding, J. P., Woo, V. C., Rohwedder, K., Sugg, J. E., & Parikh, S. J. (2012). Long-Term Effectiveness of Dapagliflozin Over 104 Weeks in Patients With Type 2 Diabetes Poorly Controlled With Insulin. In DIABETES Vol. 61 (pp. A267-A268). Retrieved from https://www.webofscience.com/
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., . . . Dapagliflozin, S. G. (2012). Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial. Annals of Internal Medicine, 156(6), 405-U50. doi:10.1059/0003-4819-156-6-201203200-00003
Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin
Rohwedder, K., Wilding, J. P. H., Woo, V., Sugg, J., & Parikh, S. (2012). Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin. In DIABETOLOGIA Vol. 55 (pp. S309). Retrieved from https://www.webofscience.com/
Nurse led counselling in a hypertension clinic in Malawi leads to improved adherence and blood pressure control
Starichi, Z., Wilding, J., Dawes, S., Lopez, T., Dreyer, G., & Allain, T. (2012). Nurse led counselling in a hypertension clinic in Malawi leads to improved adherence and blood pressure control. JOURNAL OF HUMAN HYPERTENSION, 26(10), 623-624. Retrieved from https://www.webofscience.com/
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Wilding, J. P. H. (2012). PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. DIABETES OBESITY & METABOLISM, 14(11), 973-982. doi:10.1111/j.1463-1326.2012.01601.x
Risk of Misdiagnosis, Health-Related Quality of Life, and BMI in Patients Who Are Overweight With Doctor-Diagnosed Asthma
Scott, S., Currie, J., Albert, P., Calverley, P., & Wilding, J. P. H. (2012). Risk of Misdiagnosis, Health-Related Quality of Life, and BMI in Patients Who Are Overweight With Doctor-Diagnosed Asthma. CHEST, 141(3), 616-624. doi:10.1378/chest.11-0948
Sustained reductions in weight and HbA<sub>1c</sub> with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes
Bailey, C. J., Wilding, J., Nauck, M. A., Ferrannini, E., Ptaszynska, A. A., Apanovitch, A. M., . . . Parikh, S. J. (2012). Sustained reductions in weight and HbA<sub>1c</sub> with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes. In DIABETOLOGIA Vol. 55 (pp. S295). Retrieved from https://www.webofscience.com/
The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?
Crawford, M. R., Bartlett, D. J., Coughlin, S. R., Phillips, C. L., Neill, A. M., Espie, C. A., . . . Marshall, N. S. (2012). The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?. THORAX, 67(10), 920-924. doi:10.1136/thoraxjnl-2012-201622
Treatment of Diabetes through targeting weight loss
Thondam, S., & Wilding, J. P. H. (2012). Treatment of Diabetes through targeting weight loss. In J. Vora, & J. Buse (Eds.), Evidence-based Management of Diabetes (pp. 111-130). Shrewsbury: TFM Publishing.
2011
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease
Nair, S., Hardy, K. J., & Wilding, J. P. H. (2011). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease. DIABETIC MEDICINE, 28(10), 1279. doi:10.1111/j.1464-5491.2011.03344.x
Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation
Huda, M. S. B., Dovey, T. M., Wong, S. P., English, P. J., Halford, J. C. G., McCulloch, P., . . . Pinkney, J. H. (2011). Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 165(1), 45-55. doi:10.1530/EJE-10-1122
The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease
Nair, S., Mishra, V., Hayden, K., Lisboa, P. J. G., Pandya, B., Vinjamuri, S., . . . Wilding, J. P. H. (2011). The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease. DIABETOLOGIA, 54(6), 1304-1307. doi:10.1007/s00125-011-2085-9
Therapeutics Glucagon-like peptide-1 analogues for type 2 diabetes
Wilding, J. P. H., & Hardy, K. (2011). Therapeutics Glucagon-like peptide-1 analogues for type 2 diabetes. BRITISH MEDICAL JOURNAL, 342. doi:10.1136/bmj.d410
Human RBP4 adipose tissue expression is gender specific and influenced by leptin
Kos, K., Wong, S., Tan, B. K., Kerrigan, D., Randeva, H. S., Pinkney, J. H., & Wilding, J. P. H. (2011). Human RBP4 adipose tissue expression is gender specific and influenced by leptin. CLINICAL ENDOCRINOLOGY, 74(2), 197-205. doi:10.1111/j.1365-2265.2010.03892.x
Pathophysiology and aetiology of obesity
Wilding, J. P. H. (2011). Pathophysiology and aetiology of obesity. Medicine, 39(1), 6-10. doi:10.1016/j.mpmed.2010.10.002
RBP4 adipose tissue expression in humans is gender specific and influenced by leptin
Kos, K., Wong, S., Bee, T., Kerrigan, D., Harpal, S. R., Pinkney, J. H., & Wilding, J. P. H. (2011). RBP4 adipose tissue expression in humans is gender specific and influenced by leptin. Clinical Endocrinology, 74, 197-205.
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease
Nair, S., Hardy, K. J., & Wilding, J. P. H. (2011). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease. Diabetic Medicine. doi:10.1111/j.1464-
2010
Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects
Huda, M. S. B., Mani, H., Dovey, T., Halford, J. C. G., Boyland, E., Daousi, C., . . . Pinkney, J. (2010). Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects. CLINICAL ENDOCRINOLOGY, 73(5), 678-685. doi:10.1111/j.1365-2265.2010.03865.x
Nurse-led clinics for strict hypertension control are effective long term: a 7 year follow-up study
Woodward, A., Wallymahmed, M., Wilding, J. P., & Gill, G. V. (2010). Nurse-led clinics for strict hypertension control are effective long term: a 7 year follow-up study. DIABETIC MEDICINE, 27(8), 933-937. doi:10.1111/j.1464-5491.2010.03039.x
Nurse‐led clinics for strict hypertension control are effective long term: a 7 year follow‐up study
Woodward, A., Wallymahmed, M., Wilding, J. P., & Gill, G. V. (2010). Nurse‐led clinics for strict hypertension control are effective long term: a 7 year follow‐up study. Diabetic Medicine, 27(8), 933-937. doi:10.1111/j.1464-5491.2010.03039.x
Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation
O'Neill, E. D., Wilding, J. P. H., Kahn, C. R., Van Remmen, H., McArdle, A., Jackson, M. J., & Close, G. L. (2010). Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. AGE, 32(2), 209-222. doi:10.1007/s11357-009-9125-0
SPARC: a key player in the pathologies associated with obesity and diabetes
Kos, K., & Wilding, J. P. H. (2010). SPARC: a key player in the pathologies associated with obesity and diabetes. NATURE REVIEWS ENDOCRINOLOGY, 6(4), 225-235. doi:10.1038/nrendo.2010.18
The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity
Mracek, T., Ding, Q., Tzanavari, T., Kos, K., Pinkney, J., Wilding, J., . . . Bing, C. (2010). The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. CLINICAL ENDOCRINOLOGY, 72(3), 334-341. doi:10.1111/j.1365-2265.2009.03658.x
Dapagliflozin in Patients with Type 2 Diabetes Poorly Controlled on Insulin Therapy-Efficacy of a Novel Insulin-Independent Treatment
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., & Parikh, S. (2010). Dapagliflozin in Patients with Type 2 Diabetes Poorly Controlled on Insulin Therapy-Efficacy of a Novel Insulin-Independent Treatment. In DIABETES Vol. 59 (pp. A21-A22). Retrieved from https://www.webofscience.com/
Dapagliflozin lowered rate of insulin uptitration/study discontinuation from lack of glycaemic control in 48-week study of type 2 diabetes patients poorly controlled on insulin therapy
Soler, N. G., Wilding, J. P. H., Woo, V., Pahor, A., Sugg, J., Langkilde, A., & Parikh, S. (2010). Dapagliflozin lowered rate of insulin uptitration/study discontinuation from lack of glycaemic control in 48-week study of type 2 diabetes patients poorly controlled on insulin therapy. In DIABETOLOGIA Vol. 53. Retrieved from https://www.webofscience.com/
Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin
Wilding, J. P. H., Woo, V., Pahor, A., Sugg, J., Langkilde, A., & Parikh, S. (2010). Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. In DIABETOLOGIA Vol. 53. Retrieved from https://www.webofscience.com/
In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1
Kos, K., Wong, S. P. Y., Huda, M. S. B., Cakir, M., Jernas, M., Carlsson, L., . . . Pinkney, J. H. (2010). In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. DIABETES OBESITY & METABOLISM, 12(4), 360-363. doi:10.1111/j.1463-1326.2009.01171.x
Non-invasive Ventilation and Weaning: Principles and Practice
Elliott, M., Nava, S., & Schonhofer, B. (Eds.) (n.d.). Non-invasive Ventilation and Weaning: Principles and Practice. In . CRC Press. doi:10.1201/b13434
Sodium Glucose Co transporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Nair, S., & Wilding, J. P. H. (2010). Sodium Glucose Co transporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism (JCEM), 95, 34-42.
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Nair, S., & Wilding, J. P. H. (2010). Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 95(1), 34-42. doi:10.1210/jc.2009-0473
The Endocrinologist and Respiratory Failure
Wilding, J. P. H. (2010). The Endocrinologist and Respiratory Failure. In M. Elliott, S. Nava, & B. Schönhofer (Eds.), Non-Invasive Ventilation and Weaning: Principals and Practice (pp. 210-230). London: Hodder Arnold.
The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women
Halford, J. C. G., Boyland, E. J., Cooper, S. J., Dovey, T. M., Huda, M. S. B., Dourish, C. T., . . . Wilding, J. P. H. (2010). The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. JOURNAL OF PSYCHOPHARMACOLOGY, 24(1), 99-109. doi:10.1177/0269881108095195
2009
New treatments for type 2 diabetes
Kos, K., & Wilding, J. P. H. (2009). New treatments for type 2 diabetes. Journal of the Royal College of Physicians of Edinburgh, 39(3), 227-230.
Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK
Wilding, J. (2009). Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. The British Journal of Diabetes & Vascular Disease, 9(4), 177-185. doi:10.1177/1474651409342637
Adipokines: Emerging therapeutic targets
Kos, K., & Wilding, J. P. H. (2009). Adipokines: Emerging therapeutic targets. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 10(10), 1061-1068. Retrieved from https://www.webofscience.com/
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009). A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment. DIABETES CARE, 32(9), 1656-1662. doi:10.2337/dc09-0517
Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009). Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. CLINICAL ENDOCRINOLOGY, 71(2), 195-201. doi:10.1111/j.1365-2265.2008.03451.x
Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose
Kos, K., Wong, S., Tan, B., Gummesson, A., Jernas, M., Franck, N., . . . Wilding, J. P. H. (2009). Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose. DIABETES, 58(8), 1780-1788. doi:10.2337/db09-0211
Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes
Ding, Q., Mracek, T., Gonzalez-Muniesa, P., Kos, K., Wilding, J., Trayhurn, P., & Bing, C. (2009). Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes. ENDOCRINOLOGY, 150(4), 1688-1696. doi:10.1210/en.2008-0952
Pharmacological Approaches for Treating Obesity
Wilding, J. (2009). Pharmacological Approaches for Treating Obesity. In Unknown Book (pp. 421-446). Wiley. doi:10.1002/9780470712221.ch17
Drug Therapy for the Obese Diabetic Patient
Wilding, J. P. H. (2009). Drug Therapy for the Obese Diabetic Patient. In Unknown Book (pp. 185-202). Wiley. doi:10.1002/9780470741474.ch10
Ghrelin restores 'lean-type' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects
Huda, M. S. B., Dovey, T., Wong, S. P., English, P. J., Halford, J., Mcculloch, P., . . . Pinkney, J. (2009). Ghrelin restores 'lean-type' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. INTERNATIONAL JOURNAL OF OBESITY, 33(3), 317-325. doi:10.1038/ijo.2008.270
'Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects'
Huda, M., Mani, H., Dovey, T. M., Halford, J. C., Boyland, E. J., Daousi, C., . . . Pinkney, J. (2009). 'Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects'. Obesity Facts, S2(2), 150.
Anti-obesity drugs: from animal models to the clinic
Dourish, C. T., Wilding, J. P. H., & Halford, J. C. G. (2009). Anti-obesity drugs: from animal models to the clinic. In R. A. McArthur, & F. Borsini (Eds.), Animal and translational models of CNS drug discovery - Reward Deficit Disorders (Vol. 3, pp. 271-315). London: Academic Press.
Anxiety and Depression amongst Diabetic Foot Ulcer Patients
Thomas, C. M., Thomas, J. C., Ranjan, S., Wallymahmed, M., Wallymahmed, A. H., Benbow, S. J., . . . Gill, G. V. (2009). Anxiety and Depression amongst Diabetic Foot Ulcer Patients. In DIABETES Vol. 58 (pp. A471). Retrieved from https://www.webofscience.com/
Dapagliflozin Pilot Study in Insulin-Resistant T2DM Patients
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009). Dapagliflozin Pilot Study in Insulin-Resistant T2DM Patients. In DIABETES Vol. 58 (pp. A129). Retrieved from https://www.webofscience.com/
Dapagliflozin improves glycaemic control in insulin-resistant patients with type 2 diabetes
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009). Dapagliflozin improves glycaemic control in insulin-resistant patients with type 2 diabetes. In DIABETOLOGIA Vol. 52 (pp. S76). Retrieved from https://www.webofscience.com/
Ghrelin Increases Lipid Mobilization and Respiratory Quotient Variability, Suggesting a Role in Metabolic Flexibility
Huda, M. S., Dovey, T. M., Wong, S., English, P. J., Halford, J. C. G., Hayden, K., . . . Pinkney, J. (2009). Ghrelin Increases Lipid Mobilization and Respiratory Quotient Variability, Suggesting a Role in Metabolic Flexibility. DIABETES, 58, A362. Retrieved from https://www.webofscience.com/
Modern management of obesity
Aditya, B. S., & Wilding, J. P. H. (2009). Modern management of obesity. CLINICAL MEDICINE, 9(6), 617-621. doi:10.7861/clinmedicine.9-6-617
Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care
Idris, I., Hall, A. P., O'Reilly, J., Barnett, A., Allen, M., Andrews, R., . . . Wilding, J. P. (2009). Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. DIABETES OBESITY & METABOLISM, 11(8), 733-741. doi:10.1111/j.1463-1326.2009.01045.x
Pharmacological Approaches
Wilding, J. P. H. (2009). Pharmacological Approaches. In G. Williams, & G. Fruhbeck (Eds.), Obesity: Science and Practice (pp. 340-367). Oxford: Wiley.
Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue
Kos, K., Wong, S., Tan, B., Gummesson, A., Jernas, M., Franck, N., . . . Wilding, J. P. H. (2009). Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue. In DIABETES Vol. 58 (pp. A358). Retrieved from https://www.webofscience.com/
The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1
Kos, K. T., Wong, S., Jernas, M., Kerrigan, D., Carlsson, L., Wilding, J. P. H., & Pinkney, J. H. (2009). The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. In DIABETOLOGIA Vol. 52 (pp. S282). Retrieved from https://www.webofscience.com/
The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1
Kos, K. T., Wong, S., Jernas, M., Kerrigan, D., Carlsson, L., Wilding, J. P. H., & Pinkney, J. H. (2009). The human adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. Diabetologia, 52, 719.
2008
Achieving blood pressure control in patients with type 2 diabetes and diabetic renal disease by a nurse-led protocol based clinic
Mugarza, J. A., Wilding, J. P., Woodward, A., Hayden, K., & Gill, G. V. (2008). Achieving blood pressure control in patients with type 2 diabetes and diabetic renal disease by a nurse-led protocol based clinic. The British Journal of Diabetes & Vascular Disease, 8(6), 279-284. doi:10.1177/1474651408098672
Growth hormone and changes in energy balance in growth hormone deficient adults
Deepak, D., Daousi, C., Boyland, E., Pinkney, J. H., Wilding, J. P. H., & MacFarlane, I. A. (2008). Growth hormone and changes in energy balance in growth hormone deficient adults. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 38(9), 622-627. doi:10.1111/j.1365-2362.2008.01993.x
Sleep-disordered breathing and type 2 diabetes - A report from the International Diabetes Federation Taskforce on Epidemiology and Prevention
Shaw, J. E., Punjabi, N. M., Wilding, J. P., Alberti, K. G. M. M., & Zimmet, P. Z. (2008). Sleep-disordered breathing and type 2 diabetes - A report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. DIABETES RESEARCH AND CLINICAL PRACTICE, 81(1), 2-12. doi:10.1016/j.diabres.2008.04.025
Weight management and cardiovascular disease: implications of recent and ongoing clinical trials
Wilding, J., & Finer, N. (2008). Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. The British Journal of Diabetes & Vascular Disease, 8(4), 170-176. doi:10.1177/1474651408094587
Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage
Woodward, A., Mugarza, J., Khan, M., Smith, E., Wilding, J., & Gill, G. (2008). Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage. Practical Diabetes International, 25(2), 54-58. doi:10.1002/pdi.1203
Is Obesity Realistically Treatable in Type 2 Diabetes?
Wilding, J. (2001). Is Obesity Realistically Treatable in Type 2 Diabetes?. In Unknown Book (pp. 73-87). Wiley. doi:10.1002/9780470757109.ch5
Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal
Huda, M. S. B., Durham, B. H., Wong, S. P., Deepak, D., Kerrigan, D., McCulloch, P., . . . Wilding, J. P. H. (2008). Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. INTERNATIONAL JOURNAL OF OBESITY, 32(1), 129-135. doi:10.1038/sj.ijo.0803694
'Acute administration of synthetic human GLP-1 (7-36 amide) in obese patients with type 2 diabetes mellitus decreases circulating IL-6 levels but does not alter plasma leptin and adiponectin'
Daousi, C., Wilding, J. P., Cleator, J., Durham, B. H., & Ranganath, L. (2008). 'Acute administration of synthetic human GLP-1 (7-36 amide) in obese patients with type 2 diabetes mellitus decreases circulating IL-6 levels but does not alter plasma leptin and adiponectin'. In American Endocrine Society (Ed.), 90th Annual Meeting of the American Endocrine Society (pp. 719). San Fransisco, USA: American Endocrine Society.
'Effects Of 6 Months Growth Hormone Replacement (GHR) On Pro-Inflammatory Cytokines In Adults With Severe Growth Hormone Deficiency'
Deepak, D., Daousi, C., Boyle, E., Halford, J. C., Wilding, J. P., Pinkney, J., & MacFarlane, I. A. (2008). 'Effects Of 6 Months Growth Hormone Replacement (GHR) On Pro-Inflammatory Cytokines In Adults With Severe Growth Hormone Deficiency'. In 90th Annual Meeting of the American Endocrine Society (pp. 387). San Francisco: American Endocrine Society.
'Plasma Obestatin And Ghrelin Levels During Acute Administration Of Synthetic Human GLP-1(7-36 Amide) And GIP In Obese Patients With Type 2 Diabetes And Lean Healthy Volunteers'
Daousi, C., Ranganath, L., Cleator, J., Durham, B. H., & Wilding, J. P. (2008). 'Plasma Obestatin And Ghrelin Levels During Acute Administration Of Synthetic Human GLP-1(7-36 Amide) And GIP In Obese Patients With Type 2 Diabetes And Lean Healthy Volunteers'. In American Endocrine Society (Ed.), 90th Annual Meeting of the American Endocrine Society (pp. 719). San Fransisco: American Endocrine Society.
'Plasma obestatin levels are lower in morbidly obese and post-gastrectomy subjects, but do not change in response to a meal '
Huda, M. S. B., Durham, B. H., Wong, S. P., Deepak, D., Kerrigan, D., McCulloch, P., . . . Wilding, J. P. H. (2008). 'Plasma obestatin levels are lower in morbidly obese and post-gastrectomy subjects, but do not change in response to a meal '. International Journal of Obesity, 32, 135-139.
'The influence of growth hormone (GH) replacement (GHR) in adults with GH deficiency (GHD) on resting energy expenditure, voluntary physical activity and ingestive behavior'
Deepak, D., Daousi, C., Boyle, E., Halford, J. C., Wilding, J. P., Pinkney, J., & MacFarlane, I. A. (2008). 'The influence of growth hormone (GH) replacement (GHR) in adults with GH deficiency (GHD) on resting energy expenditure, voluntary physical activity and ingestive behavior'. In 90th Annual Meeting of the American Endocrine Society (pp. 386). San Francisco: American Endocrine Society.
'Weight management and cardiovascular disease: implications of recent and ongoing clinical trials'
Wilding, J., & Finer, N. (2008). 'Weight management and cardiovascular disease: implications of recent and ongoing clinical trials'. British Journal of Diabetes and Vascular Disease, 8, 165-170.
A prospective randomised control trial of medical weight loss in obese asthmatics
Scott, S., Albert, P. S., Currie, J., Parry, P., Calverley, P. M. A., & Wilding, J. (2008). A prospective randomised control trial of medical weight loss in obese asthmatics. European Respiratory Journal, 32 (su, 1141.
A validated screening tool can be used to identify night-eaters in a UK obesity clinic
Cleator, J., James, M., Wilding, J., Sutton, C. J., & Judd, P. A. (2008). A validated screening tool can be used to identify night-eaters in a UK obesity clinic. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S116). Retrieved from https://www.webofscience.com/
Adipose tissue derived SPARC and obesity related inflammation in healthy
Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Adipose tissue derived SPARC and obesity related inflammation in healthy. In DIABETOLOGIA Vol. 51 (pp. S330-S331). Retrieved from https://www.webofscience.com/
Adipose tissue derived SPARC and obesity related inflammation in healthy adults
Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Adipose tissue derived SPARC and obesity related inflammation in healthy adults. Diabetologia, TBC, TBC.
Anti-obesity Drugs: From Animal Models to Clinical Efficacy
Dourish, C. T., Wilding, J. P. H., & Halford, J. C. G. (2008). Anti-obesity Drugs: From Animal Models to Clinical Efficacy. In Animal and Translational Models for CNS Drug Discovery (pp. 271-315). Elsevier. doi:10.1016/b978-0-12-373861-5.00028-x
Current criteria for Night Eating Syndrome (NES) exclude some aspects of night eating behaviour
Cleator, J., Wilding, J., James, M., Sutton, C. J., & Judd, P. A. (2008). Current criteria for Night Eating Syndrome (NES) exclude some aspects of night eating behaviour. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S112). Retrieved from https://www.webofscience.com/
Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance
Kos, K., Wong, S., Kerrigan, D., Pinkney, J. H., & Wilding, J. P. (2008). Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance. In DIABETES Vol. 57 (pp. A387). Retrieved from https://www.webofscience.com/
Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance
Kos, K., Wong, S., Kerrigan, D., Pinkney, J. H., & Wilding, J. P. H. (2008). Depot specific expression of SPARC in human adipose tissue, relation with adipokines and insulin resistance. Diabetes, S, P.
Distribution and characteristics of adiponectin R1 and R2 receptor in RNA gene expression in human visceral and subcutaneous adipose tissue
Pinkney, J. H., Wong, S. P. Y., Kerrigan, D., Kos, K., & Wilding, J. P. H. (2008). Distribution and characteristics of adiponectin R1 and R2 receptor in RNA gene expression in human visceral and subcutaneous adipose tissue. In DIABETOLOGIA Vol. 51 (pp. S90). Retrieved from https://www.webofscience.com/
Distribution and characteristics of adiponectin R1 and R2 receptor mRNA
Pinkney, J. H., Wong, S., Kerrigan, D., Kos, K., & Wilding, J. P. H. (2008). Distribution and characteristics of adiponectin R1 and R2 receptor mRNA. Diabetologia, TBC, TBC.
Endocrine adaptations to short term fasting are preserved after gastrectomy but impaired in morbid obesity
Huda, M., Dovey, T., Wong, S., English, P., Halford, J., McCulloch, P., . . . Pinkney, J. (2008). Endocrine adaptations to short term fasting are preserved after gastrectomy but impaired in morbid obesity. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S74). Retrieved from https://www.webofscience.com/
Energy restriction enhances therapeutic efficacy of the PPARγ agonist, rosiglitazone, through regulation of visceral fat gene expression
Moore, G. B. T., Pickavance, L. C., Briscoe, C. P., Clapham, J. C., Buckingham, R. E., & Wilding, J. P. H. (2008). Energy restriction enhances therapeutic efficacy of the PPARγ agonist, rosiglitazone, through regulation of visceral fat gene expression. DIABETES OBESITY & METABOLISM, 10(3), 251-263. doi:10.1111/j.1463-1326.2007.00697.x
Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation
Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation. In INTERNATIONAL JOURNAL OF OBESITY Vol. 32 (pp. S15). Retrieved from https://www.webofscience.com/
Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation
Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Gender differences of RBP4 expression, relation of plasma, VAT and SCAT expression and its relation with insulin resistance and inflammation. European Congress of Obesity, p, OS1.3.
How effective is bariatric surgery in diabetes?
Aditya, B. S., Magee, C., Pipara, L., Kerrigan, D., & Wilding, J. P. H. (2008). How effective is bariatric surgery in diabetes?. In DIABETIC MEDICINE Vol. 25. Retrieved from https://www.webofscience.com/
Is there a stereotyped personality amongst diabetic foot ulcer patients?
Thomas, C. M., Thomas, J., Wallymahamed, A. H., Wallymahamed, M., Benbow, S. J., Wilding, J. P., & Gill, G. V. (2008). Is there a stereotyped personality amongst diabetic foot ulcer patients?. In DIABETES Vol. 57 (pp. A756). Retrieved from https://www.webofscience.com/
Management of diabetes following bariatric surgery
Aditya, B. S., Andrews, C., Pillai, A., Kerrigan, D., & Wilding, J. P. H. (2008). Management of diabetes following bariatric surgery. In DIABETIC MEDICINE Vol. 25. Retrieved from https://www.webofscience.com/
Pharmacology of Obesity
Wilding, J. P. H. (2008). Pharmacology of Obesity. M. J. Parnham, & J. Bruinvels (Eds.), Basel: Birkhauser.
Regulation of energy balance — towards rational drug design in obesity
Harrold, J. A., & Wilding, J. P. H. (n.d.). Regulation of energy balance — towards rational drug design in obesity. In Milestones in Drug Therapy (pp. 21-46). Birkhäuser Basel. doi:10.1007/978-3-7643-7425-9_3
SPARC expression in human adipose tissue is correlated with insulin resistance and fat mass
Kos, K., Wong, S., Kerrigan, D., Pinkney, J. H., & Wilding, J. P. H. (2008). SPARC expression in human adipose tissue is correlated with insulin resistance and fat mass. Diabetic Medicine, S, P1.
The RAPSODI trial:: Goals, design, methods, and recruitment for a clinical trial of rimonabant on the time for progression to type 2 diabetes
Sjoestrom, L., Wilding, J. P., Ryan, D., Pi-Sunyer, X., & Fujioka, K. (2008). The RAPSODI trial:: Goals, design, methods, and recruitment for a clinical trial of rimonabant on the time for progression to type 2 diabetes. In DIABETES Vol. 57 (pp. A595). Retrieved from https://www.webofscience.com/
The endocannabinoid system as a target for obesity treatment
Khan, M., & Wilding, J. P. H. (n.d.). The endocannabinoid system as a target for obesity treatment. In Milestones in Drug Therapy (pp. 69-80). Birkhäuser Basel. doi:10.1007/978-3-7643-7425-9_6
The expression of the adipokine SPARC is correlated with insulin resistance and fat mass
Kos, K., Wong, S. P. Y., Kerrigan, D., Pinkneyw, J. H., & Wilding, J. P. H. (2008). The expression of the adipokine SPARC is correlated with insulin resistance and fat mass. In DIABETIC MEDICINE Vol. 25. Retrieved from https://www.webofscience.com/
Unlike subcutaneous expression of IL-6 and IL-18, omental expression of IL-6, IL-18 and MCP-1 are not related to systemic cytokine levels in human obesity
Kos, K., Wong, S., Kerrigan, D., Wilding, J. P. H., & Pinkney, J. H. (2008). Unlike subcutaneous expression of IL-6 and IL-18, omental expression of IL-6, IL-18 and MCP-1 are not related to systemic cytokine levels in human obesity. Society for Endocrinology, 15, P105.
2007
Cardiovascular disease risk modification in abdominally obese people with type 2 diabetes
Wilding, J. (2007). Cardiovascular disease risk modification in abdominally obese people with type 2 diabetes. Diabetes and Primary Care, 9(1).
Clinical Investigations of Antiobesity Drugs
Wilding, J. (2007). Clinical Investigations of Antiobesity Drugs. In Appetite and Body Weight (pp. 337-III). Elsevier. doi:10.1016/b978-012370633-1/50014-1
Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects
Huda, M. S. B., Durham, B. H., Wong, S. P., Dovey, T. M., McCulloch, P., Kerrigan, D., . . . Wilding, J. P. H. (2007). Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. BONE, 41(3), 406-413. doi:10.1016/j.bone.2007.05.006
Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
Wilding, J. P. H., Gause-Nilsson, I., Persson, A., & GALLANT 7 Study Group. (2007). Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.. Diabetes & vascular disease research, 4(3), 194-203. doi:10.3132/dvdr.2007.040
The importance of free fatty acids in the development of Type 2 diabetes
Wilding, J. P. H. (2007). The importance of free fatty acids in the development of Type 2 diabetes. DIABETIC MEDICINE, 24(9), 934-945. doi:10.1111/j.1464-5491.2007.02186.x
Effects of olanzapine in mate rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabotic abnormatities
Cooper, G. D., Pickavance, L. C., Wilding, J. P. H., Harrold, J. A., Halford, J. C. G., & Goudie, A. J. (2007). Effects of olanzapine in mate rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabotic abnormatities. JOURNAL OF PSYCHOPHARMACOLOGY, 21(4), 405-413. doi:10.1177/0269881106069637
Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study
Fatani, S., Pickavance, L. C., Sadler, C. J., Harrold, J. A., Cassidy, R., Wilding, J. P. H., & Naderali, E. K. (2007). Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study. NUTRITION & METABOLISM, 4. doi:10.1186/1743-7075-4-15
Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes
English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., . . . Wilding, J. P. H. (2007). Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. DIABETES-METABOLISM RESEARCH AND REVIEWS, 23(4), 299-303. doi:10.1002/dmrr.681
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure
Dargie, H. J., Hildebrandt, P. R., Riegger, G. A. J., McMurray, J. J. V., McMorn, S. O., Roberts, J. N., . . . Wilding, J. P. H. (2007). A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 49(16), 1696-1704. doi:10.1016/j.jacc.2006.10.077
An elderly type 1 diabetic patient with life event‐related brittle diabetes
Thomas, C., Majid, S., Wilding, J., Wallymahmed, M., & Gill, G. (2007). An elderly type 1 diabetic patient with life event‐related brittle diabetes. Practical Diabetes International, 24(3), 130-131. doi:10.1002/pdi.1075
Cardiovascular and metabolic effects of CPAP in obese males with OSA
Coughlin, S. R., Mawdsley, L., Mugarza, J. A., Wilding, J. P. H., & Calverley, P. M. A. (2007). Cardiovascular and metabolic effects of CPAP in obese males with OSA. EUROPEAN RESPIRATORY JOURNAL, 29(4), 720-727. doi:10.1183/09031936.00043306
Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease
Deepak, D., Furlong, N. J., Wilding, J. P. H., & MacFarlane, I. A. (2007). Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. POSTGRADUATE MEDICAL JOURNAL, 83(978), 277-280. doi:10.1136/pgmj.2006.052241
Treatment strategies for obesity
Wilding, J. P. H. (2007). Treatment strategies for obesity. OBESITY REVIEWS, 8, 137-144. doi:10.1111/j.1467-789X.2007.00333.x
'Does the co-administration of synthetic human GLP-1 (7-36 amide) and GIP restore the diminished insulinotropic action of GIP in obese patients with type 2 diabetes?'
Daousi, C., Wilding, J. P., Cleator, J., & Ranganath, L. (2007). 'Does the co-administration of synthetic human GLP-1 (7-36 amide) and GIP restore the diminished insulinotropic action of GIP in obese patients with type 2 diabetes?'. In 89th Annual Meeting of the American Endocrine Society (pp. 187). Toronto: The Endocrine Society.
'Effects of synthetic human GLP-1 (7-36 amide) and GIP on energy expenditure and appetite in obese patients with type 2 diabetes mellitus and in lean healthy subjects'
Daousi, C., Ranganath, L., Aditya, S., Cleator, J., & Wilding, J. P. (2007). 'Effects of synthetic human GLP-1 (7-36 amide) and GIP on energy expenditure and appetite in obese patients with type 2 diabetes mellitus and in lean healthy subjects'. In 89th Annual Meeting of the American Endocrine Society (pp. P2-P186). Toronto: The Endocrine Society.
'Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects'
Huda, M. S. B., Durham, B. H., Wong, S. P., Dovey, T. M., McCulloch, P., Kerrigan, D., . . . Wilding, J. P. H. (2007). 'Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects'. Bone, 41(3), 413-416.
A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method
Halford, J., Boyland, E., Dovey, T., Huda, M., Dourish, C., Dawson, G., & Wilding, J. (2007). A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method. Retrieved from https://www.webofscience.com/
A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method.
Halford, J. C. G., Boyland, E., Dovey, T. M., Huda, M., Dourish, C. T., Dawson, G., & Wilding, J. P. H. (2007). A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method.. International Journal of Obesity., 1(31), 151.
Changes in circulating plasma ghrelin and obestatin in narcolepsy-cataplexy
Huda, M., Mani, H., Durham, B., Dovey, T., Halford, J., Aditya, S., . . . Hart, I. (2007). Changes in circulating plasma ghrelin and obestatin in narcolepsy-cataplexy. In SLEEP Vol. 30 (pp. A218-A219). Retrieved from https://www.webofscience.com/
Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study
Fatani, S., Pickavance, L. C., Sadler, C. J., Harrold, J. A., Cassidy, R., Elliott, J., . . . Naderali, E. K. (2007). Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study. Nutrition and Metabolism, 4(15).
Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat
Pickavance, L. C., & Wilding, J. P. H. (2007). Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. DIABETES OBESITY & METABOLISM, 9(1), 114-120. doi:10.1111/j.1463-1326.2006.00586.x
Effects of S 15511, a therapeutic metabolite of the insulin‐sensitizing agent S 15261, in the Zucker Diabetic Fatty rat
Pickavance, L. C., & Wilding, J. P. H. (2007). Effects of S 15511, a therapeutic metabolite of the insulin‐sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. Diabetes, Obesity and Metabolism, 9(1), 114-120. doi:10.1111/j.1463-1326.2006.00586.x
Health related quality of life (HRQL) in patients with and without diabetic foot ulcers
Thomas, C. M., Wong, S. Y., Thomas, J. C., Wallymahmed, M., Wallymahmed, A. H., Benbow, S. J., . . . Gill, G. V. (2007). Health related quality of life (HRQL) in patients with and without diabetic foot ulcers. In DIABETES Vol. 56 (pp. A711). Retrieved from https://www.webofscience.com/
How can we best modify the risk of cardiovascular disease in type 2 diabetes patients with abdominal obesity?
Wilding, J. P. H. (2007). How can we best modify the risk of cardiovascular disease in type 2 diabetes patients with abdominal obesity?. Diabetes and Primary Care, 9(1), 16-26.
Is the modification of diet in renal disease equation suitable for estimating glomerular filtration rate in obese patients with Type 2 diabetes?
Mishra, V., Hayden, K., & Wilding, J. P. H. (2007). Is the modification of diet in renal disease equation suitable for estimating glomerular filtration rate in obese patients with Type 2 diabetes?. In DIABETIC MEDICINE Vol. 24 (pp. 77-78). Retrieved from https://www.webofscience.com/
Microangiopathic haemolytic anaemia and diabetes mellitus
Joyes, L., Bhutani, R., Daousi, C., DasGupta, R., Gill, G. V., & Wilding, J. P. H. (2007). Microangiopathic haemolytic anaemia and diabetes mellitus. DIABETIC MEDICINE, 24, 109. Retrieved from https://www.webofscience.com/
Pharmacotherapy of Obesity
Wilding, J. P. H. (Ed.) (2007). Pharmacotherapy of Obesity. Basel: Birkhauser.
Regulation of energy balance - towards rational drug design in obesity
Harrold, J. A. (2007). Regulation of energy balance - towards rational drug design in obesity. In M. J. Parnham, & J. Bruinvels (Eds.), Pharmacotherapy of Obesity (pp. IN PRESS). Basel: Birkhauser Publishing.
Standard tools used to assess eating patterns in obese populations do not encourage the reporting of night eating behaviour
Cleator, J., Wilding, J., Sutton, C., & Judd, P. (2007). Standard tools used to assess eating patterns in obese populations do not encourage the reporting of night eating behaviour. In INTERNATIONAL JOURNAL OF OBESITY Vol. 31 (pp. S128). Retrieved from https://www.webofscience.com/
2006
Pathophysiology and aetiology of obesity
Wilding, J. P. H. (2006). Pathophysiology and aetiology of obesity. Medicine, 34(12), 501-505. doi:10.1053/j.mpmed.2006.09.004
Applied physiology: The control of weight
English, P. J., & Wilding, J. P. H. (2006). Applied physiology: The control of weight. Current Paediatrics, 16(6), 439-446. doi:10.1016/j.cupe.2006.08.007
Diabetes and sleep apnoea: a hidden epidemic?
Wilding, J. (2006). Diabetes and sleep apnoea: a hidden epidemic?. THORAX, 61(11), 928-929. doi:10.1136/thx.2006.062513
Thiazolidinediones, insulin resistance and obesity: finding a balance
Wilding, J. (2006). Thiazolidinediones, insulin resistance and obesity: finding a balance. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 60(10), 1272-1280. doi:10.1111/j.1742-1241.2006.01128.x
Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes
English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., . . . Wilding, J. P. H. (2006). Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. DIABETOLOGIA, 49(9), 2219-2221. doi:10.1007/s00125-006-0344-y
Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm
Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. (2006). Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. DIABETIC MEDICINE, 23(7), 780-787. doi:10.1111/j.1464-5491.2006.01889.x
Gut peptides and the regulation of appetite
Huda, M. S. B., Wilding, J. P. H., & Pinkney, J. H. (2006). Gut peptides and the regulation of appetite. OBESITY REVIEWS, 7(2), 163-182. doi:10.1111/j.1467-789X.2006.00245.x
Obesity and risk of myocardial infarction: the INTERHEART study
Wilding, J., & Finer, N. (2006). Obesity and risk of myocardial infarction: the INTERHEART study. LANCET, 367(9516), 1053. doi:10.1016/S0140-6736(06)68463-8
Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors
Daousi, C., Casson, I. F., Gill, G. V., MacFarlane, I. A., Wilding, J. P. H., & Pinkney, J. H. (2006). Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. POSTGRADUATE MEDICAL JOURNAL, 82(966), 280-284. doi:10.1136/pmj.2005.039032
'Assessment of the potential efficacy and CNS side effects of novel serotoninergic anti-obesity agents in phase 1 clinical studies'
Dourish, C. T., Boyland, E., Halford, J. C. G., Dawson, R., & Wilding, J. P. H. (2006). 'Assessment of the potential efficacy and CNS side effects of novel serotoninergic anti-obesity agents in phase 1 clinical studies'. Journal of Pharmacological Sciences, 101, 17.
'Gut peptides and the regulation of appetite'
Huda, M. S. B., Wilding, J. P. H., & Pinkney, J. H. (2006). 'Gut peptides and the regulation of appetite'. Obesity reviews, 7(2), 780-787.
'The influence of growth hormone replacement (GHR) in adults with GH deficiency (GHD) on body composition, basal metabolic rate, physical activity and ingestive behaviour'
Deepak, D., Daousi, C., Pinkney, J., Wilding, J. P., & MacFarlane, I. A. (2006). 'The influence of growth hormone replacement (GHR) in adults with GH deficiency (GHD) on body composition, basal metabolic rate, physical activity and ingestive behaviour'. In 8th European Congress of Endocrinology (pp. 125). Glasgow: Society for Endocrinology.
Aetiology of type 2 diabetes
Huda, M. S. B., & Wilding, J. P. H. (2006). Aetiology of type 2 diabetes. Best Practice and Research in Diabetes and Endocrinology, 39-52.
Assessment of the potential efficacy and CNS side-effects of novel serotonergic anti-obesity agents in phase 1 clinical studies
Dourish, C. T., Boyland, E., Halford, J. C. G., Dawson, G. R., & Wilding, J. P. H. (2006). Assessment of the potential efficacy and CNS side-effects of novel serotonergic anti-obesity agents in phase 1 clinical studies. JOURNAL OF PHARMACOLOGICAL SCIENCES, 101, 17. Retrieved from https://www.webofscience.com/
Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. PRESIDENTS AWARD
Blundell, J. E., Jebb, S., Stubbs, R. J., Wilding, J. P. H., Lawton, C. L., Browning, L., . . . Halford, J. C. G. (2006). Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. PRESIDENTS AWARD. Obesity Reviews 7, 2(7), 104.
Ghrelin increases respiratory quotient in obese subjects. PRESIDENTS AWARD
Huda, M. S. B., Wong, S. P., Dovey, T. M., English, P. J., Halford, J. C. G., Hayden, K., . . . Pinkney, J. (2006). Ghrelin increases respiratory quotient in obese subjects. PRESIDENTS AWARD. Obesity Reviews, 2(7), 102-103.
Symptoms are poor indicators for the presence of asthma in obese adults measured by SGRQ and SF36
Scott, S. J., Currie, J., Maharjan, L., Wilding, J. P., & Calverley, P. M. (2006). Symptoms are poor indicators for the presence of asthma in obese adults measured by SGRQ and SF36. Procedings of the American Thoracic Society, 3, A527.
The metabolic syndrome - New definition, more controversy
Wilding, J. (2006). The metabolic syndrome - New definition, more controversy. Cardiometabolic Risk and Weight Management, 1(1), 2-3.
2005
Improved glycaemic control - an unintended benefit of a nurse-led cardiovascular risk reduction clinic
Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. (2005). Improved glycaemic control - an unintended benefit of a nurse-led cardiovascular risk reduction clinic. DIABETIC MEDICINE, 22(9), 1272-1274. doi:10.1111/j.1464-5491.2005.01549.x
Improved glycaemic control—an unintended benefit of a nurse‐led cardiovascular risk reduction clinic
Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. (2005). Improved glycaemic control—an unintended benefit of a nurse‐led cardiovascular risk reduction clinic. Diabetic Medicine, 22(9), 1272-1274. doi:10.1111/j.1464-5491.2005.01549.x
Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?
Daousi, C., MacFarlane, I. A., English, P. J., Wilding, J. P. H., Patterson, M., Dovey, T. M., . . . Pinkney, J. H. (2005). Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 90(9), 5025-5030. doi:10.1210/jc.2004-1874
A parametric analysis of olanzapine-induced weight gain in female rats
Cooper, G. D., Pickavance, L. C., Wilding, J. P. H., Halford, J. C. G., & Goudie, A. J. (2005). A parametric analysis of olanzapine-induced weight gain in female rats. PSYCHOPHARMACOLOGY, 181(1), 80-89. doi:10.1007/s00213-005-2224-4
Reply
Bennett, S. M. A., Heise, M., Jones, N. P., Walker, M., & Wilding, J. P. H. (2005). Reply. Diabetic Medicine, 22(5), 667. doi:10.1111/j.1464-5491.2005.01472b.x
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?
Ciardullo, A. V. (2005). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?. DIABETIC MEDICINE, 22(5), 666-667. doi:10.1111/j.1464-5491.2005.01502.x
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty? Reply
Bennett, S. M. A., Heise, M., Jones, N. P., Walker, M., & Wilding, J. P. H. (2005). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty? Reply. DIABETIC MEDICINE, 22(5), 667. doi:10.1111/j.1464-5491.2005.01472b.x
The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats
Pickavance, L. C., Brand, C. L., Wassermann, K., & Wilding, J. P. H. (2005). The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. BRITISH JOURNAL OF PHARMACOLOGY, 144(3), 308-316. doi:10.1038/sj.bjp.0706041
'Does impaired satiety contribute to human hypothalamic obesity?'
Daousi, C., English, P. J., Wilding, J. P., MacFarlane, I. A., Dovey, T. M., Halford, J. C., & Pinkney, J. H. (2005). 'Does impaired satiety contribute to human hypothalamic obesity?'. Obesity Research, 12, 322-P.
Achievements of blood pressure targets in a stand alone nurse-led clinic in type 2 diabetic patients with microalbuminuria and nephropathy.
Mugarza, J. A., Wilding, J. P. H., Woodward, A., & Gill, G. V. (2005). Achievements of blood pressure targets in a stand alone nurse-led clinic in type 2 diabetic patients with microalbuminuria and nephropathy.. Diabetic Medicine, 22, 75.
Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C
Wong, S. P. Y., Huda, M., English, P., Bargiotta, A., Wilding, J. P. H., Johnson, A., . . . Pinkney, J. H. (2005). Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. DIABETOLOGIA, 48(12), 2641-2649. doi:10.1007/s00125-005-0038-x
Adult Obesity: Diabetes, Metabolic Syndrome and NASH
Dewan, S., & Wilding, J. P. H. (2005). Adult Obesity: Diabetes, Metabolic Syndrome and NASH. In P. Kopelman, I. Caterson, & B. Dietz (Eds.), 'Obesity and related metabolic disease in adults and children' (pp. 45). Oxford: Blackwell Science.
Baseline B-type natriuretic peptide identifies patients with type 2 diabetes and class I/II heart failure at risk of fluid retention when treated with rosigiltazone
Dargle, H., Hildebrandt, P. K., Riegger, G., Wilding, J. P., McMurray, J., McMorn, S., . . . Stewart, M. W. (2005). Baseline B-type natriuretic peptide identifies patients with type 2 diabetes and class I/II heart failure at risk of fluid retention when treated with rosigiltazone. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 45 (pp. 139A). Retrieved from https://www.webofscience.com/
Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults:: a randomized, placebo-controlled trial
Zelissen, P. M. J., Stenlof, K., Lean, M. E. J., Fogteloo, J., Keulen, E. T. P., Wilding, J., . . . Williams, G. (2005). Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults:: a randomized, placebo-controlled trial. DIABETES OBESITY & METABOLISM, 7(6), 755-761. doi:10.1111/j.1463-1326.2005.00468.x
Effects of high-fat feeding and rosiglitazone treatment on hypothalamic MC4-R density
Harrold, J., Cassidy, R., Tarrach, C., Wilding, J., & Williams, G. (2005). Effects of high-fat feeding and rosiglitazone treatment on hypothalamic MC4-R density. In OBESITY RESEARCH Vol. 13 (pp. A106). Retrieved from https://www.webofscience.com/
Improved glycaemic control ¿ an unintended benefit of a nurse-led cardiovascular risk reduction clinic
Woodward, A., Wallymahmed, M., Wilding, J., & Gill, G. V. (2005). Improved glycaemic control ¿ an unintended benefit of a nurse-led cardiovascular risk reduction clinic. Diabetic Medicine.
Insulin resistance and increased markers of systemic inflammation in elderly patients with diastolic heart failure
Wisniacki, N., Lye, M., & Wilding, J. P. H. (2005). Insulin resistance and increased markers of systemic inflammation in elderly patients with diastolic heart failure. Heart, 91(1), 27-31.
Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure
Wisniacki, N., Taylor, W., Lye, M., & Wilding, J. P. H. (2005). Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. HEART, 91(1), 32-37. doi:10.1136/hrt.2003.029652
Managing the Patient wiht Newly Diagnosed Type 2 Diabetes
Wilding, J. P. H. (2005). Managing the Patient wiht Newly Diagnosed Type 2 Diabetes. Worthing: Cambridge Medical Publications.
Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy
Mugarza, J. A., Woodward, A., Wilding, J. P. H., & Gill, G. V. (2005). Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy. DIABETOLOGIA, 48, A349. Retrieved from https://www.webofscience.com/
Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy
Mugarza, J., Woodward, A., Wilding, J. P. H., & Gill, G. V. (2005). Optimising blood pressure control in the type 2 population is more achievable in the absence of microalbuminuria or nephropathy. Diabetic Medicine, 48, 960.
Rat third ventricle ependymal cells possess the ability to produce insulin
Tarrach, C. H. A., Dodson, A. A. R., Foster, C. S., Harrold, J. A., & Wilding, J. P. H. (2005). Rat third ventricle ependymal cells possess the ability to produce insulin. In DIABETES Vol. 54 (pp. A369). Retrieved from https://www.webofscience.com/
Rosiglitazone (RSG) administered to patients with type 2 diabetes (T2DM) and class I/II congestive heart failure (CHF) does not adversely affect echocardiographic structure or function parameters
Wilding, J., Dargie, H., Hildebrandt, P., Riegger, G., McMurray, J., McMorn, S., . . . Stewart, M. W. (2005). Rosiglitazone (RSG) administered to patients with type 2 diabetes (T2DM) and class I/II congestive heart failure (CHF) does not adversely affect echocardiographic structure or function parameters. In DIABETES Vol. 54 (pp. A20). Retrieved from https://www.webofscience.com/
Rosiglitazone does not adversely affect cardiac structure and function is determined by echocardiography in patients with type 2 diabetes and class I/II heart failure
Dargie, H., Hildebrandt, P. R., Riegger, G., Wilding, J. P. H., McMurray, J., McMorn, S., . . . Stewart, M. W. (2005). Rosiglitazone does not adversely affect cardiac structure and function is determined by echocardiography in patients with type 2 diabetes and class I/II heart failure. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 45 (pp. 186A). Retrieved from https://www.webofscience.com/
What should we do about the metabolic syndrome?
Wilding, J. P. H. (2005). What should we do about the metabolic syndrome?. Unknown Journal, 1, 6-9.
2004
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004). A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. INTERNATIONAL JOURNAL OF OBESITY, 28(11), 1399-1410. doi:10.1038/sj.ijo.0802783
Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meat
Dewan, S., Gillett, A., Mugarza, J. A., Dovey, T. M., Halford, J. C. G., & Wilding, J. P. H. (2004). Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meat. DIABETES-METABOLISM RESEARCH AND REVIEWS, 20(5), 405-410. doi:10.1002/dmrr.471
Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance
Sadler, C. J., & Wilding, J. P. H. (2004). Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance. BRAIN RESEARCH, 1016(2), 222-228. doi:10.1016/j.brainres.2004.05.007
Response: Postprandial adiponectin revisited
English, P. J., Coughlin, S. R., Hayden, K., Malik, I. A., & Wilding, J. P. H. (2004). Response: Postprandial adiponectin revisited. OBESITY RESEARCH, 12(6), 1032-1034. doi:10.1038/oby.2004.127
Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome
Coughlin, S. R., Mawdsley, L., Mugarza, J. A., Calverley, P. M. A., & Wilding, J. P. H. (2004). Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. EUROPEAN HEART JOURNAL, 25(9), 735-741. doi:10.1016/j.ehj.2004.02.021
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance
Bennett, S. M. A., Agrawal, A., Elashat, H., Heise, M., Jones, N. P., Walker, M., & Wilding, J. P. H. (2004). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. DIABETIC MEDICINE, 21(5), 415-422. doi:10.1111/j.1464-5491.2004.01155.x
AOD-9604 Metabolic.
Wilding, J. (2004). AOD-9604 Metabolic.. Current opinion in investigational drugs (London, England : 2000), 5(4), 436-440.
Clinical evaluation of anti-obesity drugs
Wilding, J. (2004). Clinical evaluation of anti-obesity drugs. CURRENT DRUG TARGETS, 5(3), 325-332. doi:10.2174/1389450043490479
'Ghrelin and Peptide-YY (3-36) in human hypothalamic obesity'
Daousi, C., English, P. J., Wilding, J. P. H., Patterson, M., Ghatei, M. A., MacFarlane, I. A., & Pinkney, J. H. (2004). 'Ghrelin and Peptide-YY (3-36) in human hypothalamic obesity'. In 86th Annual Meeting of the American Endocrine Society (pp. 243). New Orleans, USA: American Endocrine Society.
Body weight and prolactinoma: a retrospective study
Soran, H., Wilding, J., & MacFarlane, I. (2004). Body weight and prolactinoma: a retrospective study. INTERNATIONAL JOURNAL OF OBESITY, 28(1), 183. doi:10.1038/sj.ijo.0802492
Circulating endothelial cell adhesion molecules in women with gestational diabetes and type 1 diabetes
Dewan, S., Da Silva, N., McTernan, P., Leong, K. S., & Wilding, J. P. H. (2004). Circulating endothelial cell adhesion molecules in women with gestational diabetes and type 1 diabetes. DIABETOLOGIA, 47, A8. Retrieved from https://www.webofscience.com/
Does impaired satiety contribute to human hypothalamic obesity?
Daousi, C., English, P., Dovey, T., Macfarlane, I., Wilding, J., Halford, J., & Pinkney, J. (2004). Does impaired satiety contribute to human hypothalamic obesity?. In OBESITY RESEARCH Vol. 12 (pp. A84). Retrieved from https://www.webofscience.com/
Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose-response analysis
Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose-response analysis. Int. J. Obes., 28(suppl), S215.
Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose response analysis
Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Effects of olanzapine on body weight gain, cumulative food intake and adiposity: A dose response analysis. INTERNATIONAL JOURNAL OF OBESITY, 28, S215. Retrieved from https://www.webofscience.com/
Insulin receptors are present in third ventricle ependymal cells suggesting a role in the regulation of energy balance
Tarrach, C., Morris, R., Harrold, J., Williams, G., & Wilding, J. (2004). Insulin receptors are present in third ventricle ependymal cells suggesting a role in the regulation of energy balance. INTERNATIONAL JOURNAL OF OBESITY, 28, S224. Retrieved from https://www.webofscience.com/
Insulin resistance (IR) and markers of systemic inflammation (SI) in older patients with systolic and diastolic heart failure (DHF). Predictive value for survival
Wisniacki, N., Taylor, W., Lye, M., & Wilding, J. P. H. (2004). Insulin resistance (IR) and markers of systemic inflammation (SI) in older patients with systolic and diastolic heart failure (DHF). Predictive value for survival. HEART, 90, A49. Retrieved from https://www.webofscience.com/
Obesity treatment: the key to managing the type 2 diabetes timebomb?
Wilding, J. (2004). Obesity treatment: the key to managing the type 2 diabetes timebomb?. The British Journal of Diabetes & Vascular Disease, 4(4), 217-219. doi:10.1177/14746514040040040101
Olanzapine-induced adiposity in male Han Wistar rats: A dose-response analysis
Cooper, G., Pickavance, L., Wilding, J., Goudie, A., & Halford, J. (2004). Olanzapine-induced adiposity in male Han Wistar rats: A dose-response analysis. OBESITY RESEARCH, 12, A127. Retrieved from https://www.webofscience.com/
Olanzapine-induced changes in body weight, food intake and adiposity.
Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Olanzapine-induced changes in body weight, food intake and adiposity.. Appetite, 43, 112.
The impact of using meal-replacements verses standard dietetic advice on body weight, appetite, mood and satisfaction during a 12-week weight control program
Halford, J., Ball, M., Pontin, E., Maharjan, L., Dovey, T., Pinkney, J., . . . Mela, D. (2004). The impact of using meal-replacements verses standard dietetic advice on body weight, appetite, mood and satisfaction during a 12-week weight control program. In OBESITY RESEARCH Vol. 12 (pp. A51). Retrieved from https://www.webofscience.com/
The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency
Malik, I. A., English, P. J., Ghatei, M. A., Bloom, S. R., MacFarlane, I. A., & Wilding, J. P. H. (2004). The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. CLINICAL ENDOCRINOLOGY, 60(1), 137-141. doi:10.1111/j.1365-2265.2004.01929.x
The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency.
Malik, I. A., English, P. J., Ghatei, M. A., Bloom, S. R., MacFarlane, I. A., & Wilding, J. P. H. (2004). The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency.. Clinical endocrinology, 60(1), 137-141. doi:10.1111/j.1365-2265.2004.01929.x
Weight gain, hyperphagia and adiposity following olanzapine treatment does not significantly influence circulating leptin in rats
Cooper, G. D., Pickavance, L. C., Goudie, A. J., Wilding, J. P. H., & Halford, J. C. G. (2004). Weight gain, hyperphagia and adiposity following olanzapine treatment does not significantly influence circulating leptin in rats. Appetite, 42, 349.
2003
Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects
Malik, I. A., Foy, P., Wallymahmed, M., Wilding, J. P. H., & MacFarlane, I. A. (2003). Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. CLINICAL ENDOCRINOLOGY, 59(1), 75-81. doi:10.1046/j.1365-2265.2003.01799.x
Peripheral Injection Of Risperidone, An Atypical Antipsychotic, Alters The Body Weight Gains Of Rats
Goudie, A. J., Halford, J. C. G., Cooper, G. D., Dovey, T., Pickavance, L. C., & Wilding, J. P. H. (2003). Peripheral Injection Of Risperidone, An Atypical Antipsychotic, Alters The Body Weight Gains Of Rats. Clinical and Experimental Pharmacology and Physiology, 30(7), 513-514. doi:10.1046/j.1440-1681.2003.t01-1-03854.x
Obesity and type-2 diabetes in the elderly
Dewan, S., & Wilding, J. P. H. (2003). Obesity and type-2 diabetes in the elderly. GERONTOLOGY, 49(3), 137-145. doi:10.1159/000069176
Obesity and diabetes.
Cleator, J., & Wilding, J. (2003). Obesity and diabetes.. Nursing times, 99(15), 54-55.
Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat
Pickavance, L. C., Widdowson, P. S., Foster, J. R., Williams, G., & Wilding, J. P. H. (2003). Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 84(2), 83-89. doi:10.1046/j.1365-2613.2003.00337.x
P953 The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era
MANN, P. (2003). P953 The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era. European Heart Journal, 24(5), 159. doi:10.1016/s0195-668x(03)94245-x
The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era
Mann, P., Leong, K., Malik, I., Wilding, J., & Amadi, A. (2003). The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era. EUROPEAN HEART JOURNAL, 24, 159. doi:10.1016/S0195-668X(03)94245-X
Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal.
Dewan, S., Gillett, A., Mugarza, J. A., Dovey, T. M., Halford, J. C. G., & Wilding, J. P. H. (2003). Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal.. DIABETOLOGIA, 46, A306-A307. Retrieved from https://www.webofscience.com/
Intensified treatment of type 2 diabetes - positive effects on blood pressure, but not glycaemic control
Gill, G. V., Woodward, A., Pradhan, S., Wallymahmed, M., Groves, T., English, P., & Wilding, J. P. (2003). Intensified treatment of type 2 diabetes - positive effects on blood pressure, but not glycaemic control. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 96(11), 833-836. doi:10.1093/qjmed/hcg143
Is there a role for reduced brown adipose tissue thermogenesis in thiazolidinedione-induced weight gain?
Cassidy, R., Buckingham, R., & Wilding, J. (2003). Is there a role for reduced brown adipose tissue thermogenesis in thiazolidinedione-induced weight gain?. In DIABETES Vol. 52 (pp. A140). Retrieved from https://www.webofscience.com/
Olanzapine-induced weight gain in female han Wistar rats: A dose-response study
Cooper, G., Pickavance, L., Goudie, A., Wilding, J., & Halford, J. (2003). Olanzapine-induced weight gain in female han Wistar rats: A dose-response study. OBESITY RESEARCH, 11, A74. Retrieved from https://www.webofscience.com/
Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gain of rats
Goudie, A. J., Halford, J. C. G., Cooper, G. D., Dovey, T., Pickavance, L. C., & Wilding, J. P. H. (2003). Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gain of rats. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 30(7), 513-514. doi:10.1046/j.1440-1681.2003.t01-1-03854.x
Plasma adiponectin increases postprandially in obese, but not in lean, subjects
English, P. J., Coughlin, S. R., Hayden, K., Malik, I. A., & Wilding, J. P. H. (2003). Plasma adiponectin increases postprandially in obese, but not in lean, subjects. OBESITY RESEARCH, 11(7), 839-844. doi:10.1038/oby.2003.115
Topiramate decreases weight and blood pressure in severely obese subjects
Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F., Perry, B., & Fitchet, M. (2003). Topiramate decreases weight and blood pressure in severely obese subjects. In OBESITY RESEARCH Vol. 11 (pp. A114). Retrieved from https://www.webofscience.com/
2002
Neuropeptides and appetite control
Wilding, J. P. H. (2002). Neuropeptides and appetite control. DIABETIC MEDICINE, 19(8), 619-627. doi:10.1046/j.1464-5491.2002.00790.x
Ghrelin: sweet regulation?
English, P. J., & Wilding, J. P. H. (2002). Ghrelin: sweet regulation?. CLINICAL SCIENCE, 103(3), 329-330. doi:10.1042/cs1030329
Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study
Broom, I., Wilding, J., Stott, P., & Myers, N. (2002). Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 56(7), 494-499. Retrieved from https://www.webofscience.com/
<i>Practical Diabetes International</i> 18(9) November December 2001, page 309. ‘Attaining UKPDS management targets in type 2 diabetes’.
Woodward, A., Groves, T., Wallymahamed, M., Wilding, J. P., & Gill, G. V. (2002). <i>Practical Diabetes International</i> 18(9) November December 2001, page 309. ‘Attaining UKPDS management targets in type 2 diabetes’.. Practical Diabetes International, 19(5), 154. doi:10.1002/pdi.371
Hypothalamic obesity in humans: what do we know and what can be done?
Pinkney, J., Wilding, J., Williams, G., & MacFarlane, I. (2002). Hypothalamic obesity in humans: what do we know and what can be done?. Obesity reviews : an official journal of the International Association for the Study of Obesity, 3(1), 27-34. doi:10.1046/j.1467-789x.2002.00052.x
Food fails to suppress ghrelin levels in obese humans
English, P. J., Ghatei, M. A., Malik, I. A., Bloom, S. R., & Wilding, J. P. H. (2002). Food fails to suppress ghrelin levels in obese humans. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 87(6), 2984-2987. doi:10.1210/jc.87.6.2984
Obesity: under-diagnosed and under-treated in hospital outpatient departments
Cleator, J., Richman, E., Leong, K. S., Mawdsley, L., White, S., & Wilding, J. (2002). Obesity: under-diagnosed and under-treated in hospital outpatient departments. INTERNATIONAL JOURNAL OF OBESITY, 26(4), 581-584. doi:10.1038/sj.ijo.0801945
Applied physiology: the control of weight
English, P. J., & Wilding, J. P. H. (2002). Applied physiology: the control of weight. Current Paediatrics, 12(2), 130-137. doi:10.1054/cupe.2001.0264
Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain
Tarrach, C., Harrold, J., Cassidy, R., Wilding, J., & Williams, G. (2002). Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain. BRITISH JOURNAL OF PHARMACOLOGY, 137. Retrieved from https://www.webofscience.com/
Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain
Tarrach, C., Harrold, J., Cassidy, R., Wilding, J., & Williams, G. (2002). Involvement of hypothalamic melanocortin receptors in rosiglitazone-induced weight gain. British Journal of Pharmacology, 137. Retrieved from isi:000179658000142
Obesity: under-diagnosed and under-treated in hospital outpatient departments
Cleator, J., Richman, E., Leong, K. S., Mawdsley, L., White, S., & Wilding, J. (2002). Obesity: under-diagnosed and under-treated in hospital outpatient departments. International Journal of Obesity, 26(4), 581-584. doi:10.1038/sj.ijo.0801945
Ragaglitazar improves insulin sensitivity and metabolic profile in dietary obese, pre-diabetic and diabetic ZDF rats.
Pickavance, L., Wassermann, K., Brand, C. L., & Wilding, J. (2002). Ragaglitazar improves insulin sensitivity and metabolic profile in dietary obese, pre-diabetic and diabetic ZDF rats.. Diabetes, 51(suppl.), 576-P, A142.
The effect of respiration rate on heart rate variability and baroreflex sensitivity
Delaney, J. P. A., Coughlin, S. R., Brodie, D. A., & Wilding, J. P. H. (2002). The effect of respiration rate on heart rate variability and baroreflex sensitivity. JOURNAL OF PHYSIOLOGY-LONDON, 543, 45P-46P. Retrieved from https://www.webofscience.com/
Type 2 diabetes in practice
Pickavance, L., & Wilding, J. (2002). Type 2 diabetes in practice. Br J Cardiol, 9, 448.
Type 2 diabetes in practice
Pickavance, L., & Wilding, J. (2002). Type 2 diabetes in practice. Unknown Journal, 9, 448.
2001
An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease
Leong, K. S., Walker, A. B., Martin, I., Wile, D., Wilding, J., & MacFarlane, I. A. (2001). An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. CLINICAL ENDOCRINOLOGY, 54(4), 463-468. doi:10.1046/j.1365-2265.2001.01169.x
Attaining UKPDS management targets in type 2 diabetes: failures and difficulties
Woodward, A., Groves, T., Wallymahamed, M., Wilding, J. P., & Gill, G. V. (2001). Attaining UKPDS management targets in type 2 diabetes: failures and difficulties. Practical Diabetes International, 18(9), 307-310. doi:10.1002/pdi.275
Leptin and the control of obesity.
Wilding, J. P. (2001). Leptin and the control of obesity.. Current opinion in pharmacology, 1(6), 656-661. doi:10.1016/s1471-4892(01)00111-4
The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency
Leong, K. S., Mann, P., Wallymahmed, M., MacFarlane, I. A., & Wilding, J. P. H. (2001). The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. CLINICAL ENDOCRINOLOGY, 54(6), 819-826. doi:10.1046/j.1365-2265.2001.01267.x
Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols
Naderali, E. K., Brown, M. J., Pickavance, L. C., Wilding, J. P. H., Doyle, P. J., & Williams, G. (2001). Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. CLINICAL SCIENCE, 101(5), 499-506. doi:10.1042/CS20010088
Errata
Errata (2001). Clinical Endocrinology, 55(4), 563. doi:10.1046/j.1365-2265.2001.01409.x
Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight
NADERALI, E. K., PICKAVANCE, L. C., WILDING, J. P. H., & WILLIAMS, G. (2001). Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. Clinical Science, 100(6), 635-641. doi:10.1042/cs1000635
Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight
Naderali, E. K., Pickavance, L. C., Wilding, J. P. H., & Williams, G. (2001). Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. CLINICAL SCIENCE, 100(6), 635-641. doi:10.1042/CS20000279
Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats
Naderali, E. K., Pickavance, L. C., Wilding, J. P. H., Doyle, P. J., & Wiliams, G. (2001). Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. EUROPEAN JOURNAL OF PHARMACOLOGY, 416(1-2), 133-139. doi:10.1016/S0014-2999(01)00866-4
Causes of obesity
P.H. Wilding, J. (2001). Causes of obesity. Practical Diabetes International, 18(8), 288-292. doi:10.1002/pdi.277
Insulin sensitisation by rosiglitazone: Effects on metabolism and gene exression
Moore, G. B. T., Pickavance, L. C., Clapham, J. C., Carter, S., Briscoe, C., Tadayyon, M., . . . Wilding, J. P. H. (2001). Insulin sensitisation by rosiglitazone: Effects on metabolism and gene exression. DIABETOLOGIA, 44, A28. Retrieved from https://www.webofscience.com/
Insulin sensitising effect of rosiglitazone: Effects on metabolism and gene expression.
Moore, G., Pickavance, L., Clapham, J., Carter, S., Bond, B., Buckingham, R., & Wilding, J. P. H. (2001). Insulin sensitising effect of rosiglitazone: Effects on metabolism and gene expression.. Diabetes, 50(suppl.), 2128-PO, A506.
Insulin sensitising effect of rosiglitazone: Effects on metablism and gene expression
Moore, G., Pickavance, L., Clapham, J., Carter, S., Bond, B., Buckingham, R., & Wilding, J. P. H. (2001). Insulin sensitising effect of rosiglitazone: Effects on metablism and gene expression. In DIABETES Vol. 50 (pp. A506). Retrieved from https://www.webofscience.com/
Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia
Pickavance, L. C., Buckingham, R. E., & Wilding, J. P. H. (2001). Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. DIABETES OBESITY & METABOLISM, 3(3), 171-180. doi:10.1046/j.1463-1326.2001.00120.x
Rosiglitazone improves glycaemic and insulinaemic responses in subjects with impaired glucose tolerance
Elasha, H., Agrawal, A., Jones, N. P., Bennett, S. M. A., Walker, M., & Wilding, J. (2001). Rosiglitazone improves glycaemic and insulinaemic responses in subjects with impaired glucose tolerance. DIABETOLOGIA, 44, A221. Retrieved from https://www.webofscience.com/
Rosiglitazone improves insulin sensitivity and 24-hour ambulatory blood pressure in subjects with IGT
Bennett, S. M. A., Jones, N. P., Agrawal, A., Elasha, H., Walker, M., & Wilding, J. (2001). Rosiglitazone improves insulin sensitivity and 24-hour ambulatory blood pressure in subjects with IGT. DIABETOLOGIA, 44, A200. Retrieved from https://www.webofscience.com/
Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y
Brown, M., Bing, C., King, P., Pickavance, L., Heal, D., & Wilding, J. (2001). Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y. BRITISH JOURNAL OF PHARMACOLOGY, 132(8), 1898-1904. doi:10.1038/sj.bjp.0704030
Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y
Brown, M., Bing, C., King, P., Pickavance, L., Heal, D., & Wilding, J. (2001). Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wister rats independently of hypothalamic neuropeptide Y. British Journal of Pharmacology, 132(8), 1898. Retrieved from isi:000168326100031
Sleep disordered breathing--a new component of syndrome x?
Coughlin, S., Calverley, P., & Wilding, J. (2001). Sleep disordered breathing--a new component of syndrome x?. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2(4), 267-274. doi:10.1046/j.1467-789x.2001.00045.x
2000
Hypercalcaemia of hypoadrenal crisis mistaken for hypercalcaemia of malignancy in a patient with known bone metastases: a case report.
Stanaway, S. E., & Wilding, J. P. (2000). Hypercalcaemia of hypoadrenal crisis mistaken for hypercalcaemia of malignancy in a patient with known bone metastases: a case report.. European journal of internal medicine, 11(6), 348-350. doi:10.1016/s0953-6205(00)00119-9
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
Heymsfield, S. B., Segal, K. R., Hauptman, J., Lucas, C. P., Boldrin, M. N., Rissanen, A., . . . Sjöström, L. (2000). Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. ARCHIVES OF INTERNAL MEDICINE, 160(9), 1321-1326. doi:10.1001/archinte.160.9.1321
Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone
Cai, X. J., Lister, C. A., Buckingham, R. E., Pickavance, L., Wilding, J., Arch, J. R. S., . . . Williams, G. (2000). Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. MOLECULAR BRAIN RESEARCH, 77(1), 131-137. doi:10.1016/S0169-328X(00)00041-3
Management of hypertension (multiple letters)
Wilding, J., Williams, G., Drummond, G., Marshall, T., Rouse, A., Eisenberg, J., . . . Russell, G. (2000). Management of hypertension (multiple letters). British Medical Journal, 320(7234), 576-580.
Management of hypertension - Ideal body weight is not realistic goal for lifestyle intervention
Wilding, J., & Williams, G. (2000). Management of hypertension - Ideal body weight is not realistic goal for lifestyle intervention. BRITISH MEDICAL JOURNAL, 320(7234), 576. doi:10.1136/bmj.320.7234.576
Management of hypertension. Guidelines have serious weaknesses.
Marshall, T., & Rouse, A. (2000). Management of hypertension. Guidelines have serious weaknesses.. BMJ (Clinical research ed.), 320(7234), 576-577. doi:10.1136/bmj.320.7234.576
Abnormal heart rate variability in adults with growth hormone deficiency
Leong, K. S., Mann, P., Wallymahmed, M., MacFarlane, I. A., & Wilding, J. P. H. (2000). Abnormal heart rate variability in adults with growth hormone deficiency. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 85(2), 628-633. doi:10.1210/jc.85.2.628
Effects of chronic <i>in vivo</i> administration of troglitazone on <i>in vitro</i> contractility of rat mesenteric arteries
Naderali, E. K., Pickavance, L., Wilding, J., & Williams, G. (2000). Effects of chronic <i>in vivo</i> administration of troglitazone on <i>in vitro</i> contractility of rat mesenteric arteries. JOURNAL OF PHYSIOLOGY-LONDON, 523, 143P-144P. Retrieved from https://www.webofscience.com/
Greater weight loss on sibutramine significantly improves lipid profile: Meta-analysis of six 12-month studies
Williams, G., Wilding, J., & Wickens, M. (2000). Greater weight loss on sibutramine significantly improves lipid profile: Meta-analysis of six 12-month studies. OBESITY RESEARCH, 8, 90S. Retrieved from https://www.webofscience.com/
Highly palatable diet-induced vascular dysfunction is independent of the degree of increase in total body weight
Naderali, E. K., Pickavance, L. C., Wilding, J. P. H., Doyle, P. J., & Williams, G. (2000). Highly palatable diet-induced vascular dysfunction is independent of the degree of increase in total body weight. JOURNAL OF PHYSIOLOGY-LONDON, 526, 46P-47P. Retrieved from https://www.webofscience.com/
Obesity and Type 2 diabetes mellitus
Wilding, J. (2000). Obesity and Type 2 diabetes mellitus. DIABETIC MEDICINE, 17(5), 400-402. doi:10.1046/j.1464-5491.2000.00292-5.x
Obesity and diabetes
Wilding, J. (2000). Obesity and diabetes. CME Bulletin Endocrinology and Diabetes, 3(1), 12-14.
Sound familiar?
Wilding, J., Cook, S., & Davis, J. (2000). Sound familiar?. PSYCHOLOGIST, 13(11), 558-562. Retrieved from https://www.webofscience.com/
The future of obesity treatment.
Wilding, J. (2000). The future of obesity treatment.. EXS, 89, 181-191. doi:10.1007/978-3-0348-8393-1_11
1999
Hypothalamic orexin expression - Modulation by blood glucose and feeding
Cai, X. J., Widdowson, P. S., Harrold, J., Wilson, S., Buckingham, R. E., Arch, J. R. S., . . . Williams, G. (1999). Hypothalamic orexin expression - Modulation by blood glucose and feeding. DIABETES, 48(11), 2132-2137. doi:10.2337/diabetes.48.11.2132
Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes
Leong, K. S., Wallymahmed, M., Wilding, J., & MacFarlane, L. (1999). Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. POSTGRADUATE MEDICAL JOURNAL, 75(886), 467-470. doi:10.1136/pgmj.75.886.467
Changes in orexin mRNA during altered energy balance: Influences of leptin and insulin
Cai, X., Tadayyon, M., Buckingham, R., Wilson, S., Arch, J. R. S., Widdowson, P. S., . . . Williams, G. (1999). Changes in orexin mRNA during altered energy balance: Influences of leptin and insulin. BRITISH JOURNAL OF PHARMACOLOGY, 126, U7. Retrieved from https://www.webofscience.com/
Hypothalamic neuropeptide Y and its neuroendocrine regulation by leptin
Widdowson, P. S., & Wilding, J. P. H. (2000). Hypothalamic neuropeptide Y and its neuroendocrine regulation by leptin. NEUROENDOCRINOLOGY OF LEPTIN, 26, 71-86. Retrieved from https://www.webofscience.com/
Hypothalamic orexin expression - Modulation by blood glucose and feeding
Cai, X. J., Widdowson, P. S., Harrold, J., Wilson, S., Buckingham, R. E., Arch, J. R. S., . . . Williams, G. (1999). Hypothalamic orexin expression - Modulation by blood glucose and feeding. Diabetes, 48(11), 2132. Retrieved from isi:000083267200003
Insulin-sensitising action of rosiglitazone is enhanced by food restriction.
Pickavance, L., Buckingham, R., & Wilding, J. (1999). Insulin-sensitising action of rosiglitazone is enhanced by food restriction.. Diabetologia, 42(suppl.), 674, A181.
Insulin-sensitising action of rosiglitazone is enhanced by food restriction.
Pickavance, L., Buckingham, R., & Wilding, J. (1999). Insulin-sensitising action of rosiglitazone is enhanced by food restriction.. DIABETOLOGIA, 42, A181. Retrieved from https://www.webofscience.com/
Obesity and diabetes
Leong, K. S., & Wilding, J. P. (1999). Obesity and diabetes. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 13(2), 221-237. doi:10.1053/beem.1999.0017
Orlistat-induced weight loss improves insulin resistance in obese patients.
Wilding, J. (1999). Orlistat-induced weight loss improves insulin resistance in obese patients.. DIABETOLOGIA, 42, A215. Retrieved from https://www.webofscience.com/
The thiazolidinedione, MCC-555, prevents nitric oxide synthase induction in the pancreas of the ZDF rat.
Pickavance, L. C., Widdowson, P. S., Foster, J. R., Ishii, S., Tanaka, H., & Williams, G. (1999). The thiazolidinedione, MCC-555, prevents nitric oxide synthase induction in the pancreas of the ZDF rat.. Br. J. Pharmacol., 128, 116P.
Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution
Pickavance, L. C., Tadayyon, M., Widdowson, P. S., Buckingham, R. E., & Wilding, J. P. H. (1999). Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. BRITISH JOURNAL OF PHARMACOLOGY, 128(7), 1570-1576. doi:10.1038/sj.bjp.0702932
1998
The eat of the land: The obesity epidemic and how overweight Americans can help themselves
Wilding, J. (1998). The eat of the land: The obesity epidemic and how overweight Americans can help themselves. NATURE, 391(6669), 759. doi:10.1038/35793
Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction
Kooner, J. S., Baliga, R. R., Wilding, J., Crook, D., Packard, C. J., Banks, L. M., . . . Scott, J. (1998). Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 18(7), 1021-1026. doi:10.1161/01.ATV.18.7.1021
Obesity treatment with orlistat (xenical®) helps to prevent deterioration in glucose tolerance
Wilding, J. P. H., & Stolshek, B. (1998). Obesity treatment with orlistat (xenical®) helps to prevent deterioration in glucose tolerance. DIABETOLOGIA, 41, A126. Retrieved from https://www.webofscience.com/
Rosiglitazone therapeutic index: separation of glucose lowering and haemodilution.
Pickavance, L., Widdowson, P. S., Buckingham, R. E., & Wilding, J. P. H. (1998). Rosiglitazone therapeutic index: separation of glucose lowering and haemodilution.. Diabetologia, 41(suppl), 924, A239.
Rosiglitazone therapeutic index: Separation of efficacy and haemodilution
Pickavance, L., Widdowson, P. S., Buckingham, R. E., & Wilding, J. P. H. (1998). Rosiglitazone therapeutic index: Separation of efficacy and haemodilution. DIABETOLOGIA, 41, A239. Retrieved from https://www.webofscience.com/
Therapeutic index for rosiglitazone in dietary obese rats and effects on body weight and plasma leptin.
Pickavance, L., Tadayyon, M., Widdowson, P., Buckingham, R., & Wilding, J. (1998). Therapeutic index for rosiglitazone in dietary obese rats and effects on body weight and plasma leptin.. British Diabetic Association Meeting, Harrogate., n/a, n/a.
1997
Science, medicine, and the future - Obesity treatment
Wilding, J. (1997). Science, medicine, and the future - Obesity treatment. BRITISH MEDICAL JOURNAL, 315(7114), 997-&. doi:10.1136/bmj.315.7114.997
Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome
Jones, S. A. V., Dunnill, M. G. S., Wilding, J., Liddell, K., Gorsuch, A. N., Bloom, S. R., & Black, M. M. (1997). Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 9(1), 68-73. doi:10.1111/j.1468-3083.1997.tb00231.x
Endocrine effects of gastrointestinal tumours
Wilding, J. P. H. (1997). Endocrine effects of gastrointestinal tumours. ENDOCRINE-RELATED CANCER, 4(2), 179-189. doi:10.1677/erc.0.0040179
A simple probabilistic approach to classification and routing
Leistensnider, J., & Wilding, J. (1997). A simple probabilistic approach to classification and routing. In MILCOM 97 PROCEEDINGS, VOLS 1-3 (pp. 750-754). Retrieved from https://www.webofscience.com/
Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats
Wilding, J. P. H., Ajala, M. O., Lambert, P. D., & Bloom, S. R. (1997). Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. JOURNAL OF ENDOCRINOLOGY, 152(3), 365-369. doi:10.1677/joe.0.1520365
Correction: Science, medicine, and the future: Obesity treatment (British Medical Journal (1997) 18 October (997-1000))
Wilding, J. (1997). Correction: Science, medicine, and the future: Obesity treatment (British Medical Journal (1997) 18 October (997-1000)). British Medical Journal, 315(7122), 1599.
Earwitness testimony: Never mind the variety, hear the length
Cook, S., & Wilding, J. (1997). Earwitness testimony: Never mind the variety, hear the length. APPLIED COGNITIVE PSYCHOLOGY, 11(2), 95-111. Retrieved from https://www.webofscience.com/
Glucagon-like peptide-1 (GLP-1): A trial of treatment in noninsulin-dependent diabetes mellitus
Todd, J. F., Wilding, J. P. H., Edwards, C. M. B., Khan, F. A., Ghatei, M. A., & Bloom, S. R. (1997). Glucagon-like peptide-1 (GLP-1): A trial of treatment in noninsulin-dependent diabetes mellitus. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 27(6), 533-536. doi:10.1046/j.1365-2362.1997.1490691.x
Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome
VAUGHANJONES, S., DUNNILL, M., WILDING, J., LIDDELL, K., GORSUCH, A., BLOOM, S., & BLACK, M. (1997). Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. Journal of the European Academy of Dermatology and Venereology, 9(1), 68-73. doi:10.1016/s0926-9959(97)00602-8
Neurobiology
Wilding, J., Widdowson, P., & Williams, G. (1997). Neurobiology. BRITISH MEDICAL BULLETIN, 53(2), 286-306. Retrieved from https://www.webofscience.com/
Science, medicine, and the future: Obesity treatment (vol 315, pg 997, 1997)
Wilding, J. (1997). Science, medicine, and the future: Obesity treatment (vol 315, pg 997, 1997). BRITISH MEDICAL JOURNAL, 315(7122), 1599. Retrieved from https://www.webofscience.com/
1996
Metabolic actions of neuropeptide Y and their relevance to obesity
Wilding, J. P. H. (1996). Metabolic actions of neuropeptide Y and their relevance to obesity. BIOCHEMICAL SOCIETY TRANSACTIONS, 24(2), 576-581. doi:10.1042/bst0240576
Reduced NPY induced feeding in diabetic but not steroid-treated rats: Lack of evidence for changes in receptor number or affinity
Morgan, D. G. A., Lambert, P. D., Smith, D. M., Wilding, J. P. H., & Bloom, S. R. (1996). Reduced NPY induced feeding in diabetic but not steroid-treated rats: Lack of evidence for changes in receptor number or affinity. JOURNAL OF NEUROENDOCRINOLOGY, 8(4), 283-290. doi:10.1046/j.1365-2826.1996.04565.x
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., OShea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., . . . Bloom, S. R. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. NATURE, 379(6560), 69-72. doi:10.1038/379069a0
Reactive (AA) systemic amyloidosis
Allen, A. R., Scott, J., Clutterbuck, E., Walport, M. J., Davies, K., Wilding, J., & Thompson, M. (1996). Reactive (AA) systemic amyloidosis. British Medical Journal, 312(7038), 1087-1089.
Reactive (AA) systemic amyloidosis - A cause of refractory nephrotic syndrome
Allen, A. R., Scott, J., Clutterbuck, E., Walport, M. J., Davies, K., Wilding, J., & Thompson, M. (1996). Reactive (AA) systemic amyloidosis - A cause of refractory nephrotic syndrome. BRITISH MEDICAL JOURNAL, 312(7038), 1087-1089. Retrieved from https://www.webofscience.com/
1995
ACUTE EFFECTS OF CENTRAL NEUROPEPTIDE-Y INJECTION ON GLUCOSE-METABOLISM IN FASTED RATS
WILDING, J. P. H., KRUSZYNSKA, Y. T., LAMBERT, P. D., & BLOOM, S. R. (1995). ACUTE EFFECTS OF CENTRAL NEUROPEPTIDE-Y INJECTION ON GLUCOSE-METABOLISM IN FASTED RATS. CLINICAL SCIENCE, 89(5), 543-548. doi:10.1042/cs0890543
C-FOS EXPRESSION IN THE PARAVENTRICULAR NUCLEUS OF THE HYPOTHALAMUS FOLLOWING INTRACEREBROVENTRICULAR INFUSIONS OF NEUROPEPTIDE-Y
LAMBERT, P. D., PHILLIPS, P. J., WILDING, J. P. H., BLOOM, S. R., & HERBERT, J. (1995). C-FOS EXPRESSION IN THE PARAVENTRICULAR NUCLEUS OF THE HYPOTHALAMUS FOLLOWING INTRACEREBROVENTRICULAR INFUSIONS OF NEUROPEPTIDE-Y. BRAIN RESEARCH, 670(1), 59-65. doi:10.1016/0006-8993(94)01224-6
METABOLIC PHENOTYPES FOR GENETIC-ANALYSIS IN CORONARY HEART-DISEASE
KOONER, J. S., BALIGA, R. R., WILDING, J., PEART, S., AITMAN, T. J., & SCOTT, J. (1995). METABOLIC PHENOTYPES FOR GENETIC-ANALYSIS IN CORONARY HEART-DISEASE. CIRCULATION, 92(8), 76. Retrieved from https://www.webofscience.com/
1994
EFFECT OF FOOD-DEPRIVATION AND STREPTOZOTOCIN-INDUCED DIABETES ON HYPOTHALAMIC NEUROPEPTIDE-Y RELEASE AS MEASURED BY A RADIOIMMUNOASSAY-LINKED MICRODIALYSIS PROCEDURE
LAMBERT, P. D., WILDING, J. P. H., TURTON, M. D., GHATEI, M. A., & BLOOM, S. R. (1994). EFFECT OF FOOD-DEPRIVATION AND STREPTOZOTOCIN-INDUCED DIABETES ON HYPOTHALAMIC NEUROPEPTIDE-Y RELEASE AS MEASURED BY A RADIOIMMUNOASSAY-LINKED MICRODIALYSIS PROCEDURE. BRAIN RESEARCH, 656(1), 135-140. doi:10.1016/0006-8993(94)91374-9
GLP-17-36NH(2) IN THE CONTROL OF FOOD-INTAKE IN THE PARTIALLY SATIATED RAT
TURTON, M. D., LAMBERT, P. D., WILDING, J. P. H., GHATEI, M. A., & BLOOM, S. R. (1994). GLP-17-36NH(2) IN THE CONTROL OF FOOD-INTAKE IN THE PARTIALLY SATIATED RAT. REGULATORY PEPTIDES, 51(3), 295. doi:10.1016/0167-0115(94)90113-9
DIETARY ADVICE BASED ON THE GLYCEMIC INDEX IMPROVES DIETARY PROFILE AND METABOLIC CONTROL IN TYPE-2 DIABETIC-PATIENTS
FROST, G., WILDING, J., & BEECHAM, J. (1994). DIETARY ADVICE BASED ON THE GLYCEMIC INDEX IMPROVES DIETARY PROFILE AND METABOLIC CONTROL IN TYPE-2 DIABETIC-PATIENTS. DIABETIC MEDICINE, 11(4), 397-401. doi:10.1111/j.1464-5491.1994.tb00292.x
LACK OF ACUTE EFFECT OF AMYLIN (ISLET ASSOCIATED POLYPEPTIDE) ON INSULIN SENSITIVITY DURING HYPERINSULINEMIC EUGLYCEMIC CLAMP IN HUMANS
WILDING, J. P. H., KHANDANNIA, N., BENNET, W. M., GILBEY, S. G., BEACHAM, J., GHATEI, M. A., & BLOOM, S. R. (1994). LACK OF ACUTE EFFECT OF AMYLIN (ISLET ASSOCIATED POLYPEPTIDE) ON INSULIN SENSITIVITY DURING HYPERINSULINEMIC EUGLYCEMIC CLAMP IN HUMANS. DIABETOLOGIA, 37(2), 166-169. doi:10.1007/s001250050088
NALOXONE-INDUCED ANOREXIA INCREASES NEUROPEPTIDE-Y CONCENTRATIONS IN THE DORSOMEDIAL HYPOTHALAMUS - EVIDENCE FOR NEUROPEPTIDE-Y OPIOID INTERACTIONS IN THE CONTROL OF FOOD-INTAKE
LAMBERT, P. D., WILDING, J. P. H., ALDOKHAYEL, A. A. M., GILBEY, S. G., GHATEI, M. A., & BLOOM, S. R. (1994). NALOXONE-INDUCED ANOREXIA INCREASES NEUROPEPTIDE-Y CONCENTRATIONS IN THE DORSOMEDIAL HYPOTHALAMUS - EVIDENCE FOR NEUROPEPTIDE-Y OPIOID INTERACTIONS IN THE CONTROL OF FOOD-INTAKE. PEPTIDES, 15(4), 657-660. doi:10.1016/0196-9781(94)90091-4
1993
A ROLE FOR GLP-1(7-36)NH2 IN THE CENTRAL CONTROL OF FEEDING-BEHAVIOR
LAMBERT, P. D., WILDING, J. P. H., GHATEI, M. A., & BLOOM, S. R. (1993). A ROLE FOR GLP-1(7-36)NH2 IN THE CENTRAL CONTROL OF FEEDING-BEHAVIOR. DIGESTION, 54(6), 360-361. Retrieved from https://www.webofscience.com/
THE EFFECT OF CENTRAL BLOCKADE OF KAPPA-OPIOID RECEPTORS ON NEUROPEPTIDE Y-INDUCED FEEDING IN THE RAT
LAMBERT, P. D., WILDING, J. P. H., ALDOKHAYEL, A. A. M., GILBEY, S. G., & BLOOM, S. R. (1993). THE EFFECT OF CENTRAL BLOCKADE OF KAPPA-OPIOID RECEPTORS ON NEUROPEPTIDE Y-INDUCED FEEDING IN THE RAT. BRAIN RESEARCH, 629(1), 146-148. doi:10.1016/0006-8993(93)90493-7
A ROLE FOR NEUROPEPTIDE-Y, DYNORPHIN, AND NORADRENALINE IN THE CENTRAL CONTROL OF FOOD-INTAKE AFTER FOOD-DEPRIVATION
LAMBERT, P. D., WILDING, J. P. H., ALDOKHAYEL, A. A. M., BOHUON, C., COMOY, E., GILBEY, S. G., & BLOOM, S. R. (1993). A ROLE FOR NEUROPEPTIDE-Y, DYNORPHIN, AND NORADRENALINE IN THE CENTRAL CONTROL OF FOOD-INTAKE AFTER FOOD-DEPRIVATION. ENDOCRINOLOGY, 133(1), 29-32. doi:10.1210/en.133.1.29
INCREASED NEUROPEPTIDE-Y MESSENGER-RIBONUCLEIC-ACID (MESSENGER-RNA) AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB/OB) MOUSE
WILDING, J. P. H., GILBEY, S. G., BAILEY, C. J., BATT, R. A. L., WILLIAMS, G., GHATEI, M. A., & BLOOM, S. R. (1993). INCREASED NEUROPEPTIDE-Y MESSENGER-RIBONUCLEIC-ACID (MESSENGER-RNA) AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB/OB) MOUSE. ENDOCRINOLOGY, 132(5), 1939-1944. doi:10.1210/en.132.5.1939
A role for neuropeptide-Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation.
Lambert, P. D., Wilding, J. P., al-Dokhayel, A. A., Bohuon, C., Comoy, E., Gilbey, S. G., & Bloom, S. R. (1993). A role for neuropeptide-Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation.. Endocrinology, 133(1), 29-32. doi:10.1210/endo.133.1.8100519
AMYLIN DOES NOT AFFECT INSULIN SENSITIVITY IN HUMANS
WILDING, J. P. H., KHANDANNIA, N., GILBEY, S. G., BENNET, W. M., BEACHAM, J., GHATEI, M. A., & BLOOM, S. R. (1993). AMYLIN DOES NOT AFFECT INSULIN SENSITIVITY IN HUMANS. DIABETOLOGIA, 36, A135. Retrieved from https://www.webofscience.com/
INCREASES IN NEUROPEPTIDE-Y CONTENT AND GENE-EXPRESSION IN THE HYPOTHALAMUS OF RATS TREATED WITH DEXAMETHASONE ARE PREVENTED BY INSULIN
WILDING, J. P. H., GILBEY, S. G., LAMBERT, P. D., GHATEI, M. A., & BLOOM, S. R. (1993). INCREASES IN NEUROPEPTIDE-Y CONTENT AND GENE-EXPRESSION IN THE HYPOTHALAMUS OF RATS TREATED WITH DEXAMETHASONE ARE PREVENTED BY INSULIN. NEUROENDOCRINOLOGY, 57(4), 581-587. doi:10.1159/000126410
INTERACTIONS BETWEEN NEUROPEPTIDE-Y AND THE KAPPA-OPIOID SYSTEM IN THE CENTRAL CONTROL OF FOOD-INTAKE
LAMBERT, P. D., WILDING, J. P. H., & BLOOM, S. R. (1993). INTERACTIONS BETWEEN NEUROPEPTIDE-Y AND THE KAPPA-OPIOID SYSTEM IN THE CENTRAL CONTROL OF FOOD-INTAKE. BRITISH JOURNAL OF PHARMACOLOGY, 110, P60. Retrieved from https://www.webofscience.com/
Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse.
Wilding, J. P., Gilbey, S. G., Bailey, C. J., Batt, R. A., Williams, G., Ghatei, M. A., & Bloom, S. R. (1993). Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse.. Endocrinology, 132(5), 1939-1944. doi:10.1210/endo.132.5.7682936
1992
INCREASED NEUROPEPTIDE-Y MESSENGER-RNA AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB OB) MOUSE
WILDING, J. P. H., LAMBERT, P. D., GILBEY, S. G., BAILEY, C. J., BATT, R. A. L., WILLIAMS, G., . . . BLOOM, S. R. (1992). INCREASED NEUROPEPTIDE-Y MESSENGER-RNA AND DECREASED NEUROTENSIN MESSENGER-RNA IN THE HYPOTHALAMUS OF THE OBESE (OB OB) MOUSE. REGULATORY PEPTIDES, 39(2-3), 259. doi:10.1016/0167-0115(92)90566-D
DEXFENFLURAMINE TREATMENT AND HYPOTHALAMIC NEUROPEPTIDES IN DIET-INDUCED OBESITY IN RATS
WILDING, J. P. H., GILBEY, S. G., JONES, P. M., MANNAN, M. M., GHATEI, M. A., & BLOOM, S. R. (1992). DEXFENFLURAMINE TREATMENT AND HYPOTHALAMIC NEUROPEPTIDES IN DIET-INDUCED OBESITY IN RATS. PEPTIDES, 13(3), 557-563. doi:10.1016/0196-9781(92)90089-L
INCREASED NEUROPEPTIDE-Y CONTENT IN INDIVIDUAL HYPOTHALAMIC NUCLEI, BUT NOT NEUROPEPTIDE-Y MESSENGER-RNA, IN DIET-INDUCED OBESITY IN RATS
WILDING, J. P. H., GILBEY, S. G., MANNAN, M., ASLAM, N., GHATEI, M. A., & BLOOM, S. R. (1992). INCREASED NEUROPEPTIDE-Y CONTENT IN INDIVIDUAL HYPOTHALAMIC NUCLEI, BUT NOT NEUROPEPTIDE-Y MESSENGER-RNA, IN DIET-INDUCED OBESITY IN RATS. JOURNAL OF ENDOCRINOLOGY, 132(2), 299-304. doi:10.1677/joe.0.1320299
1991
Dexamethasone-induced increase in hypothalamic neuropeptide Y (NPY) is reversed by insulin
Wilding, J. P. H., Gilbey, S. G., Aslam, N., Ghatei, M. A., & Bloom, S. R. (1991). Dexamethasone-induced increase in hypothalamic neuropeptide Y (NPY) is reversed by insulin. Regulatory Peptides, 35(3), 262. doi:10.1016/0167-0115(91)90164-c
1990
ELEVATED HYPOTHALAMIC NEUROPEPTIDE-Y CONCENTRATIONS IN RATS FED A PALATABLE DIET-EFFECT OF D-FENFLURAMINE
WILDING, J., GILBEY, S. G., MANNAN, M., DOMIN, J., ASLAN, N., GHATEI, M. A., & BLOOM, S. R. (1990). ELEVATED HYPOTHALAMIC NEUROPEPTIDE-Y CONCENTRATIONS IN RATS FED A PALATABLE DIET-EFFECT OF D-FENFLURAMINE. REGULATORY PEPTIDES, 30(1), 59. doi:10.1016/0167-0115(90)90182-V
1989
RELATIONS BETWEEN READING AND MUSICAL ABILITIES
BARWICK, J., VALENTINE, E., WEST, R., & WILDING, J. (1989). RELATIONS BETWEEN READING AND MUSICAL ABILITIES. BRITISH JOURNAL OF EDUCATIONAL PSYCHOLOGY, 59, 253-257. doi:10.1111/j.2044-8279.1989.tb03097.x
1984
INDEPENDENCE OF SLOPE AND INTERCEPT IN STERNBERG MEMORY-SCANNING PARADIGM
VALENTINE, J., WILDING, J., & MOHINDRA, N. (1984). INDEPENDENCE OF SLOPE AND INTERCEPT IN STERNBERG MEMORY-SCANNING PARADIGM. BRITISH JOURNAL OF MATHEMATICAL & STATISTICAL PSYCHOLOGY, 37(MAY), 122-127. doi:10.1111/j.2044-8317.1984.tb00793.x
1982
THE EFFECT OF FORWARD AND BACKWARD-MASKING BY FLASH ON APPARENT SIZE
WILDING, J. (1982). THE EFFECT OF FORWARD AND BACKWARD-MASKING BY FLASH ON APPARENT SIZE. PERCEPTION, 11(2), 153-162. doi:10.1068/p110153
1969
MANAGERIAL GOALS AND INDIVIDUAL NEEDS IN SALESMENS COMPENSATION PLANS
DEWHURST, R. E., WILDING, J., & SUOJANEN, W. W. (1969). MANAGERIAL GOALS AND INDIVIDUAL NEEDS IN SALESMENS COMPENSATION PLANS. ATLANTA ECONOMIC REVIEW, 19(4), 14-16. Retrieved from https://www.webofscience.com/
1968
CONSUMER GOALS AND REACTIONS TO A COMMUNICATION SOURCE
WILDING, J., & BAUER, R. A. (1968). CONSUMER GOALS AND REACTIONS TO A COMMUNICATION SOURCE. JOURNAL OF MARKETING RESEARCH, 5(1), 73-77. doi:10.2307/3149797
INDUSTRIAL PURCHASING - SOME INSIGHTS FROM CONSUMER BEHAVIOR
WILDING, J. (1968). INDUSTRIAL PURCHASING - SOME INSIGHTS FROM CONSUMER BEHAVIOR. ATLANTA ECONOMIC REVIEW, 18(6), 6-&. Retrieved from https://www.webofscience.com/